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Abstract 
 
Prenylated indole alkaloids are a class of natural products with great structural 
diversity and pharmaceutical potential. These alkaloids, which are isolated from 
various fungi, mostly Aspergillus and Penicillium, are often produced by homologous 
dimodular non-ribosomal peptide synthetase (NRPS) pathways that combine two 
amino acids, typically tryptophan, proline, histidine or phenylalanine, to form the 
alkaloid skeleton. A unique bicyclo[2.2.2]diazaoctane group is a distinctive feature of 
the NRPS pathway of malbrancheamide, a calmodulin inhibitor produced by 
Malbranchea aurantiaca. The bicyclo[2.2.2]diazaoctane is proposed to form via an 
intramolecular Diels-Alder reaction, but the protein that ensures stereospecificity of 
the reaction is unknown. This thesis describes research focused on the structural and 
biochemical characterization of the early steps in the malbrancheamide biosynthetic 
pathway, which precedes the proposed Diels-Alder reaction. In collaborative studies, I 
solved the first crystal structure of a fungal NRPS terminal reductase domain, PhqB R 
in the homologous paraherquamide pathway, which indicates that it functions as a 2-
electron or 4-electron reductase. I also solved a 1.6 Å crystal structure of MalC, a 
candidate for re-oxidation of a potential 4-electron reduction product. However, the 
MalC structure strongly indicates that it cannot catalyze a redox reaction and its 
function remains to be characterized. Furthermore, MalB and MalE, two
xii 
 
prenyltransferases in the pathway, were characterized in detail. In summary, the 
dissertation research provides the first structural and biochemical insights into the 
early steps of malbrancheamide biosynthesis and will guide protein engineering and 
chemoenzymatic synthesis of related compounds in the future. 
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Chapter I  
Introduction 
 
1.1 Natural Products 
Natural products are secondary metabolites produced by microbes and plants [1-4]. 
With complex and diversified structures, they are not essential for survival of the 
producing organisms in absence of environmental stress. However, many natural 
products have potent biological activities, which are often utilized by the producing 
organisms to their advantage, for example by suppressing the growth of pathogenic 
and rival organisms [2]. Many natural products and their derivatives have been 
identified and further developed as antibiotics, anti-fungal agents, immuno-
suppressants and anti-cancer drugs [3-5]. 
There is a long history of using plants and herbs that produce natural products as 
medicine, toxins, etc. [6] Artemisia annua, an annual ephemeral plant, was used in 
traditional Chinese medicine for treatments of fever and malaria, a fatal mosquito-
borne infectious disease, over 1500 years ago [7] (Fig. 1.1.A). In Europe willow bark 
extract was the major medication for pain relief and fever treatment for a long period 
[8] (Fig. 1.1.B). However, it was unknown how and why these substances were 
effective, due to lack of experimental methods for small molecule isolation and 
identification. We now know that salicin, a natural product produced by willow bark, 
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can be enzymatically hydrolyzed to salicylic alcohol, which is further oxidized to 
salicylic acid (aspirin), the active ingredient [8]. As for Artemisia annua, the 
compound that kills the malaria protozoa is artemisinin (qinghaosu) [7]. With 
development of modern science, we now understand that not only plants, but also 
bacteria and fungi are abundant sources of natural products with great pharmaceutical 
potential. For example, penicillins, which were initially discovered and isolated from 
Penicillium notatum by Fleming, Florey and other researchers [9-10], are a group of 
widely used natural product drugs with potent anti-bacterial activities. 
 
 
Figure 1.2. Examples of plant natural products and their producing organisms. A. 
Artemisia annua, an annual ephemeral plant for malaria treatment, and its biologically 
active compound artemisinin. B. Willow bark produces anti-inflammatory salicin. C. 
Structure of the nicotine alkaloid and its natural source tobacco leaves. 
 
Studies of natural products are crucial for many reasons. First, natural products are 
now the major source for developing new drugs. About 50% of drugs approved by the 
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U.S. Food and Drug Administration (FDA) in the most recent 25 years are either 
natural products or their derivatives/mimics [11] (Fig. 1.2). Studies of new natural 
products will greatly benefit the discovery and development of novel drugs. Many 
natural products have also led to the discovery and characterization of important 
regulatory systems throughout life, for example, the mechanistic target of rapamycin 
(mTOR) [12-14]. Many others can function as biolabels and allow scientists to target 
macromolecules and pathways of interest. 
 
 
Figure 1.2. Source of FDA-approved drugs in 1981 – 2014 [11]. Natural products, 
mimics and derivatives contribute to 46% of the total, being the major source. 
 
Direct isolation or extraction from producing organisms was the major method to 
obtain natural product. However, this can be difficult and inefficient, with 
complicated processes and extremely low yields. For example, bryostatin 1, a 
biologically potent marine macrolide, can be extracted from marine-derived Bugula 
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neritina in only about 1.3 × 10-6 % yield [15-16]. Furthermore, many bacteria and 
fungi that produce the target compounds cannot be cultured on a large scale under 
laboratory conditions. For plants with a long life span, for example, Taxus brevifolia 
(the pacific yew), the producer of the anti-cancer paclitaxel, a shortage of the natural 
resource is also a major limitation for large-scale production. In contrast, for many 
years, chemical synthesis (total synthesis and semi synthesis) has been applied with 
great success to the production of desired compounds at a lower cost than extraction 
from the natural source. Penicillin V, for example, can be chemically synthesized from 
penicilloic acids in five steps [17]. In fact, natural products have been a driving force 
for the development of modern organic chemistry and synthetic chemistry by 
providing intriguing chemistry, challenging targets, as well as novel synthetic 
schemes. One example is the developing field of biomimetic synthesis, which targets 
synthesis of natural products through biosynthetically related intermediate structures 
[18]. 
Despite rapid development of synthetic chemistry, there are still limitations for 
generating desired natural products by chemical synthesis. To date many compounds 
cannot be chemically synthesized in a productive way. Synthesis of others requires 
multiple steps and/or extreme conditions for catalysis. For example, total synthesis of 
bryostatins takes over 40 steps [19]. Furthermore, a single modification to the target 
molecule may disable the original synthetic scheme, in which case an entirely 
different scheme must be investigated. Also many natural products have stereo centers 
and various tailoring groups, which are often essential for biological activity. 
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Structural complication generally increases the difficulty of developing novel natural 
product total synthetic schemes. Studies of natural product biosynthetic pathways 
provide an alternative approach: chemoenzymatic synthesis. 
 
1.2 Natural Product Biosynthetic Pathways 
All natural products are produced by enzymes of secondary metabolic pathways in the 
producing organisms. In microbes the biosynthetic enzymes are often encoded in gene 
clusters, which can be identified by whole genome sequencing and genomic data 
mining. In addition, many enzymes involved in natural product biosynthesis catalyze 
unique chemistry with uncommon mechanisms. Identification of genes and, 
biochemical and structural characterization of the encoded enzymes can greatly 
expand the limits of enzymology, as well as guide protein engineering and 
chemoenzymatic synthesis of novel compounds. 
Many interesting secondary metabolic pathways are modular, and can be further 
classified as type I polyketide synthase (PKS) pathways and non-ribosomal peptide 
synthetase (NRPS) pathways [20-21]. Type I PKS pathways are homologous with the 
metazoan type I fatty acid synthase (FAS) pathway, an essential primary metabolite 
pathway for de novo synthesis of fatty acids. PKS pathways are composed of 
sequential modules, each containing a set of elongation and modification domains. 
The substrate or intermediate is attached to an acyl carrier protein (ACP) domain via a 
4′-phosphopantetheine linker (Ppant arm) [22-24]. Each module accepts the 
intermediate from the ACP of its upstream module, elongates the chain by two carbon 
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atoms, catalyzes certain modification reactions, and passes the product to the ACP of 
the downstream module. When the small molecule cargo reaches the last (terminal) 
module, the thioester bond between the intermediate and the Ppant arm is cleaved and 
the cargo is released. In some cases, the offloaded product goes through another series 
of modifications catalyzed by other enzymes in the pathway to generate the final 
natural product. 
Non-ribosomal peptide synthetase (NRPS) pathways are enzyme complexes utilizing 
amino acids to generate dipeptides or polypeptides. Although evolutionarily not 
related to PKS pathways, NRPSs also use peptidyl carrier protein (PCP, also named as 
a thiolation or T domain), a similar carrier system to load and transport cargo [25-26]. 
The substrate (amino acid) is loaded onto the starting module, passed to the 
downstream modules through cycles of elongation and modification dependent on the 
domain composition of each module, and offloaded in the terminal module to 
generate the product. 
These assembly-line like modular systems have drawn great interest from researchers 
since they were identified, due to the fact that each domain catalyzes only one 
reaction in the biosynthetic scheme, with the reaction order in the assembly-line 
generally following the domain order. This provides a hope for building an efficient 
chemoenzymatic synthesis platform, where synthesis of a target molecule can be 
achieved by simple genetic manipulation to swap, delete, insert and/or modify target 
domains. Numerous studies have been done to understand the reaction mechanisms, 
substrate specificities and domain-domain interactions of these modular biosynthetic 
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pathways [22-26]. In favorable cases, researchers are now capable of engineering a 
natural pathway to produce desired novel compounds. However, to date the efficiency 
is still far below an industrially applicable level, with very low yields (μg - mg level) 
and low percent conversion of starting materials (< 1%) [27]. Identifying and studying 
new modular secondary metabolite pathways, may help to add promising novel 
“enzymatic toolboxes” to our current synthetic schemes, as well as improve our 
understanding of modular assembly-line systems. 
 
1.3 Prenylated fungal indole alkaloids 
Prenylated indole alkaloids are a class of natural products isolated from different 
fungi, mostly Aspergillus and Penicillium [28]. They are often produced by 
homologous dimodular NRPS pathways, utilizing proline, histidine, phenylalanine or 
tryptophan as substrates [29]. Prenylated indole alkaloids are unique for several 
reasons. First, many of them have complex ring systems and stereocenters. 
Stephacidin B, for example, contains two bicyclo[2.2.2]diazaoctane rings, a nitrone, a 
hydroxyindole, and nine stereocenters, with fifteen rings in total [30] (Fig. 1.3). The 
unique bicyclo[2.2.2]diazaoctane ring system, a structural feature common to this 
type of prenylated indole alkaloid, was not reported previously. 
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Figure 1.3. Examples of prenylated fungal indole alkaloids and their producing 
organisms. The bicyclo[2.2.2]diazaoctane ring is a common feature, and total 
enantiomers ((-)-1, (+)-1) have been discovered in different producing organisms. The 
natural products are colored according to the starting materials for biosynthesis (blue 
L-Trp, green L-Pro, red isoprene). 
 
Prenylation of aromatics/indoles is another key feature of this group of secondary 
metabolites. Aromatic prenyltransferases exist widely in different species of bacteria 
and fungi, catalyzing transfer of isoprenyl moieties from donors such as dimethylallyl 
diphosphate (DMAPP) and geranyl diphosphate (GPP) to specific aromatic acceptors, 
tryptophan for example [31]. Prenylation is a primary source of the structural 
complexity of prenylated indole alkaloids [32]. For fungal indole alkaloids, DMAPP 
is usually the prenyl donor, and the added prenyl group is often incorporated into 
specific rings in later steps. 
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Most previously identified aromatic prenyltransferases have broad substrate 
selectivity. For instance, CdpNPT from Aspergillus fumigatus can catalyze reverse 
prenylation of (S)-benzodiazepinedione, (R)-benzodiazepinedione, several cyclic 
peptides, and tryptophan [33]. This substrate promiscuity can be explained by the 
nature of the substrate binding pockets [34-36], which include a largely hydrophobic 
area accommodating the substrate primarily via nonspecific hydrophobic interactions. 
However, several fungal indole alkaloid pathways seem to be exceptions. Two fungal 
aromatic prenyltransferases, NotC and NotF, have been characterized from the (-)-
notoamide pathway in Aspergillus sp. MF297-2, and show narrow substrate 
selectivity and prenylation site specificity [37]. Enzymatic activity tests of NotF with 
different indole compounds show that its natural substrate (brevianamide F) is the 
only compound that triggers catalysis. Whether the strict substrate selectivity is 
characteristic of these fungal pathways requires further investigation. 
In recent decades, more prenylated fungal indole alkaloids have been isolated and 
identified, for example, the brevianamides, aspergamides, sclerotamides, macfortines, 
stephacidins, notoamides, paraherquamides and malbrancheamides [38]. They share 
similar core structural features, while having different tailoring groups and drastically 
different biological activities, ranging from anti-cancer cytotoxicity to calmodulin 
inhibition. Studies of this group of compounds and their biosynthetic pathways may 
reveal biochemical and structural basis for their peculiarity, providing innovative 
ideas and thoughts for synthesis of similar complicated ring systems. 
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1.4 Notoamide, paraherquamide and malbrancheamide pathways 
Notoamides are a group of prenylated indole alkaloids isolated from the marine-
derived fungus Aspergillus sp. MF297-2. Notoamide A-C are anticancer agents, 
showing cytotoxicity to HeLa and L1210 cell lines, with moderate IC50 values (22 - 
52 µg/mL) [39]. Very interestingly, enantiomers of notoamides have been found in 
different Aspergillus strains [40] (Fig. 1.3). In Aspergillus sp. MF297-2, (-)-
notoamide A is produced as the final pathway product. However, in Aspergillus 
versicolor, only (+)-notoamide A has been isolated. One or several enantiodivergent 
steps are proposed to be present in the biosynthetic pathways to produce either set of 
the enantiomers. 
Paraherquamides are isolated from Penicillium paraherquei in 1981 [41]. 
Paraherquamide has been shown to possess anthelmintic activity, with 91% efficacy 
against Strongyloides stercoralis, a common gastrointestinal nematode of dogs [42]. 
In calves the activity is more robust, with >95% efficacy against 8 different species of 
nematodes: Haemonchus placei, Ostertagia ostertagi, Trichostrongylus axei, 
Trichostrongylus colubriformis, Cooperia oncophora, Nematodirus helvetianus, 
Oesophagostomum radiatum, and Dictyocaulus viviparous [43]. 
Malbrancheamide is a novel phytotoxic alkaloid isolated from marine-derived 
Malbranchea aurantiaca in 2006 [44]. It was shown to inhibit radical growth of 
Amaranthus hypochondriacus using a Petri dish bioassay. Further kinetic studies with 
the calmodulin (CaM)-sensitive phosphodiesterase PDE-1 showed that 
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malbrancheamide is a moderately strong competitive inhibitor of calmodulin (Ki = 
47.4±5.63 μM). 
Through whole genome sequencing, genome mining and deep gene annotation, David 
Sherman (University of Michigan) identified the gene clusters for (-)-notoamide A in 
Aspergillus sp. MF297-2, (+)-notoamide A in Aspergillus versicolor NRRL35600, 
paraherquamide A in Penicillium fellutanum ATCC20841 and malbrancheamide in 
Malbranchea aurantiaca RRC1813 [40] (Fig. 1.4). 
 
 
Figure 1.4. Gene cluster scheme for (-)/(+)-notoamide (not/not’), paraherquamide 
(phq) and malbrancheamide (mal) pathways [40]. Comparative analysis suggests a 
common mechanism for producing precursors. Colors indicate common predicted 
functions for the encoded enzymes in these pathways. 
 
Comparative analysis indicates that these pathways are homologous, based on high 
sequence similarities and close relations of core genes in the pathways. Successful 
total synthesis and biomimetic synthesis for several prenylated indole alkaloids, 
pioneered by Robert Williams (Colorado State University), for example stephacidins 
A and B, notoamide B-D [45-49], allowed isotope-labeled feeding studies that 
significantly improved the understanding of these pathways by identifying common 
precursors and upstream-downstream relationships of labeled molecules [50-52]. 
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Combined with BLAST-based function prediction [68] for each gene product, a 
scheme was proposed to explain how the pathways synthesize their final products 
[40]. 
For the (-)-notoamide pathway, the early steps have been established by the Sherman 
group [37, 50, 53] (Fig. 1.5). The first step is an NRPS-catalyzed reaction in which the 
NotE NRPS dimodule takes L-Pro and L-Trp as substrates and produces 
brenvianamide F, a common precursor of notoamides and stephacidins. 
Brenvianamide F is then prenylated by NotF, a prenyltransferase, to generate 
deoxybrevianamide E, which can be further oxidized to 6-OH-deoxybrevianamide E. 
NotC, the other prenyltransferase in the pathway, prenylates 6-OH- 
deoxybrevianamide E to form notoamide S. 
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Figure 1.5. Proposed scheme for (-)/(+)-notoamide biosynthesis [40]. 
 
From notoamide S, the pathway branches. NotD, an FAD-dependent oxidase, 
catalyzes the pyran ring closure on notoamide S to generate notoamide E. Notoamide 
T, a dioxopiperazine, is also generated from notoamide S, and the 
bicyclo[2.2.2]diazaotane ring of notoamide T is proposed to arise from a putative 
intramolecular Diels-Alder cycloaddition reaction (IMDA). D,L-[13C]2- notoamide T 
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was synthesized chemically and fed to both Aspergillus sp. MF297-2 and Aspergillus 
versicolor, the strains that produce the notoamide enantiomers [54]. In Aspergillus 
versicolor, 13C labeled (+)-stephacidin A, a non-endogenous natural metabolite, was 
isolated, as well as the endogenous natural metabolite (+)-notoamide B. This suggests 
that notoamide T is the precursor for stephacidin A, and (-)-stephacidin A is converted 
in A. versicolor to (+)-notoamide B by a stereo-selective enzyme, probably via an 
oxidative pinacol ring rearrangement. This enzyme was later revealed to be a FAD-
dependent monooxygenase NotI’ (personal communication from Hong Tran in the 
Sherman group). In Aspergillus sp. MF297-2, both (+), (-)-[13C]2-stephacidin A and 
(-), (+)-[13C]2-notoamide B were detected, indicating the same reaction scheme, but 
no evident stereoselectivity was observed. It is still unknown how many step(s) in 
both (+)- and (-)-notoamide pathways provide strict stereocontrol, and which enzyme 
is the (first) determining factor. 
Compared to the (+)-/(-)-notoamide pathways, the paraherquamide and 
malbrancheamide pathways have one major difference: instead of forming 
dioxopiperazines, all identified products are monooxopiperazines (Fig. 1.3). The 
reductive state difference is proposed to arise from different domain compositions of 
the starting NRPS [40]. In the notoamide pathway, the terminal module of the NRPS 
(NotE) is a condensation domain, while in the other two pathways, a terminal 
reductase domain is proposed to reduce the dipeptide substrate to an aldehyde or 
alcohol. 
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Another important difference among these homologous pathways is that, compared to 
the notoamide and paraherquamide pathways, which both produce more than eight 
different products, the malbrancheamide pathway is much simpler. Only four natural 
products, premalbrancheamide, malbrancheamide B, isomalbrancheamide B and 
malbrancheamide, were isolated from Malbranchea aurantiaca, and they differ only 
in the number of halides within the structures. The gene cluster encodes seven 
proteins in total. Based on knowledge of the homologous notoamide and 
paraherquamide pathways, a 4-step reaction scheme (Fig. 1.6) is proposed [40]: 
MalG, an NRPS, utilizes L-Pro and L-Trp to produce L-Pro-L-Trp aldehyde. A 
prenyltransfer reaction then leads to a prenylated dipeptidyl aldehyde, which would 
go through a hypothetical Diels-Alder reaction to form premalbrancheamide, the 
monooxopiperazine with a bicyclo[2.2.2]diazaoctane ring. Premalbrancheamide and 
its analogs have been isolated from extracts of several different fungi, suggesting that 
its formation may be a common mechanism for biosynthesis of many fungal indole 
alkaloids. The final step is halogenation to install two chlorine atoms on the indole, 
producing malbrancheamide as the final product of the pathway. 
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Figure 1.6. Proposed scheme for malbrancheamide biosynthesis [40]. 
 
To date, the biggest question for fungal indole alkaloid biosynthesis has not been fully 
addressed, which is how the unique bicyclo[2.2.2]diazaoctane ring is synthesized 
enzymatically. The diazaoctane ring was proposed to arise from a Diels-Alder 
reaction, yet no direct evidence has been reported. As the shortest pathway in the 
family, the malbrancheamide pathway provides a great platform to answer this 
question. 
 
1.5 Intramolecular [4+2] Diels-Alder Reactions 
The Diels-Alder reaction (D-A) is a [4+2] cycloaddition reaction between a 
conjugated diene and dienophile that forms up to four stereocenters in one step (Fig. 
1.7). Depending on whether the diene and the dienophile come from the same 
molecule/substrate, Diels-Alder reactions are classified as intermolecular or 
intramolecular. As a textbook reaction in organic chemistry and synthetic chemistry, 
the Diels-Alder reaction is one of the most important ring forming reactions, with 
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broad application in total synthesis of numerous compounds [55-57]. When 
addressing complicated synthetic puzzles, most of which are delivered by natural 
products, Diels-Alder reactions sometimes offer solutions and shortcuts that no other 
reaction scheme can provide. One major reason is that Diels-Alder reactions are 
energetically favorable, and many bimolecular Diels-Alder reactions proceed at 
detectable rates without a catalyst, providing high efficiency. 
 
 
Figure 1.7. Diels-Alder reaction. The newly formed bonds are colored in red. 
 
In nature, different groups of Diels-Alder product-like structures have been isolated 
and identified, for example, the bicyclo[2.2.2]diazaoctane ring. Whether a “Diels-
Alderase”, an enzyme catalyzing Diels-Alder reactions, exists has been debated over 
decades [58-61]. The chemistry of the reaction is relatively simple and well 
understood. Frontier molecular orbital theory [55] predicts that improvement of the 
reaction rate can be achieved simply by narrowing the energy gap between the highest 
occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital 
(LUMO), suggesting the possibility that such enzymes may exist. More interestingly, 
without a catalyst, a Diels-Alder reaction can occur in two ways to generate a mixture 
18 
 
of enantiomers. However, all proposed natural Diels-Alder products possess only one 
configuration, indicating involvement of at least one enzyme to provide stereo 
control. 
Before any Diels-Alderase was identified in nature, the Baker group computationally 
designed a group of unnatural bimolecular Diels-Alderases with high stereospecificity 
and substrate selectivity [62]. Using the ROSETTA computational design 
methodology [69], they successfully converted diisopropylfluorophosphatase and 
ketosteroid isomerase scaffolds into Diels-Alder catalysts, with fewer than fifteen 
amino acid substitutions in each case. Further modification by site-directed 
mutagenesis gave rise to a Diels-Alder catalyst (DA_20_10) possessing both strict 
stereoselectivity and substrate specificity as predicted. 
Known enzymes that solely catalyze Diels-Alder reactions are very rare, although 
catalytic antibodies with Diels-Alderase activity have been generated [137]. Fungal 
macrophomate synthase (MPS), a Mg2+-dependent enzyme that synthesizes benzoate 
from 2-pyrone and oxalacetate in a five-step reaction, was proposed to catalyze an 
inverse-electron demand Diels-Alder reaction in the second step [58] (Fig. 1.8). The 
crystal structure of MPS in complex with pyruvate was reported by the Tanaka group 
in 2003 [59]. However, MPS was subsequently shown to be a Michael-aldolase but 
not a Diels-Alderase [60]. Using mixed quantum and molecular mechanics (QM/MM) 
with Monte Carlo simulations and free-energy perturbation (FEP) calculations, the 
transition state (TS) energy of the reaction was calculated, either through a concerted 
Diels-Alder reaction model or a stepwise Michael-aldol reaction model. The 
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computational calculation showed that the TS energy for the concerted model was at 
least 20 kcal/mol higher than that of the Michael-aldol model, indicating that the 
reaction is not catalyzed by a concerted mechanism, which is a defining characteristic 
of Diels-Alder reaction. 
 
 
Figure 1.8. Proposed reaction pathway for the second step of fungal macrophomate 
synthase catalysis: Diels-Alder route and Michael-aldol route [60]. Newly formed 
bonds are colored in red. 
 
Despite the many ongoing debates, the first confirmed intramolecular Diels-Alder 
enzyme, SpnF, was found in the spinosyn A biosynthetic pathway [63]. It catalyzes an 
intramolecular [4+2] cycloaddition reaction from an alkenyl to a dienyl group, 
increasing the reaction rate by 500-fold. A high-resolution crystal structure of SpnF 
was reported in 2015 [64] (Fig. 1.9.A). Bearing an S-adenosylmethionine (SAM)-
dependent methyltransferase (MT) fold, the structure resembles Class I SAM-
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dependent MTs. It is unknown whether SAM has a primarily structural role, although 
no single point mutation was identified that totally abolished cyclization activity. No 
catalytic residue has been identified, suggesting that the primary role of SpnF may be 
as an entropy trap, holding the substrate in an optimal conformation so that the 1,3-
diene and the alkene group are in proximity and positioned for the [4+2] 
cycloaddition reaction. 
In 2015, another group of homologous Diels-Alder enzymes was reported to catalyze 
stereoselective IMDA reactions to generate spirotetronate natural products [65]. The 
crystal structure of one member, PyrI4, in complex with its product, was reported in 
2016 [66] (Fig. 1.9.B). With no sequence identity to SpnF, PyrI4 is a homodimer, with 
each chain forming an antiparallel β barrel, and is structurally unrelated to SpnF. The 
product sits at the bottom of the β barrel pocket, and an initially disordered N-terminal 
region packs into a highly bent α helix (α0), closing the active site pocket. α0 is 
essential for enzymatic activity, as deletion led to the loss of Diels-Alder activity. 
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Figure 1.9. Structures of two Diels-Alder enzymes: SpnF (A) and PyrI4 (B) (figure 
from references [64] and [66]). These two enzymes are structurally unrelated. No 
catalytic residues were identified, suggesting an entropy trapping mechanism. 
 
In summary, all evidence suggest that Diels-Alder enzymes do exist in nature, 
utilizing an entropy trapping mechanism to achieve catalysis of a concerted [4+2] 
cycloaddition reaction [63-67]. High-resolution crystal structures have also provided 
insights into how nature evolved the enzymes, which intriguingly agrees well with the 
ROSETTA de novo design methodology [69]. It appears that in both cases, random 
scaffolds suitable for accommodating the substrates are selected and evolved towards 
lowering the transition state energy. Further research may provide additional details of 
this unique type of “catalytic” reaction, as well as lead to further optimization of the 
current computational protein design scheme. No enzyme in the malbrancheamide 
pathway shows similarity to either group of identified Diels-Alder enzymes. The 
malbrancheamide pathway provides a perfect object for novel Diels-Alder enzyme 
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investigation, and is the focus of my dissertation research.
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Chapter II  
MalG: A dimodular NRPS with a terminal reductase domain 
 
2.1 Introduction 
Non-ribosomal peptide synthetases (NRPSs) are multi-domain enzymes that use 
amino acids to produce various peptidyl secondary metabolites such as cyclosporin 
and tyrocidine [4, 5]. Although NRPSs form the same kind of bonds (peptide bonds) 
as ribosomes, their substrate recognition and loading, intermediate transfer and 
product release processes are largely different [70-72]. Because they can use modified 
or unnatural amino acids [73], NRPSs generate peptidyl natural products of great 
structural diversity that ribosomes can never achieve. Moreover, NRPSs contain 
different sets of domains that can further modify peptides by methylation, acylation, 
ring cyclization, etc. NRPS and hybrid polyketide synthase (PKS) – NRPS pathways 
exist in various types of bacteria and fungi, many NRPS products have potent 
biological activities, and some have been widely used as antibiotics, anti-fungal 
agents, immuno-suppressants and anti-cancer drugs [74-78] (Fig. 2.1). Well-known 
examples include aminoadipoyl-cysteinyl-valine (ACV) synthetase, which produces 
the ACV tripeptide, a precursor of penicillins and cephalosporins [74], and 
cyclosporin [75] from the fungus Tolypocladium inflatum, which produces the 
immuno-suppressant drug cyclosporine. 
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Figure 2.1. Examples of NRPS natural products. ACV is an intermediate of penicillin 
biosynthesis; cyclosporin is a widely-used immuno-suppressant; tyrocidine was the 
first commercially available antibiotic; ergotamine was an anti-migraine drug; 
bleomycin is an anti-cancer drug. 
 
Working as an assembly line, NRPSs are often modular, with a minimal module 
composed of an adenylation (A) domain, a thiolation (T or PCP) domain and a 
condensation (C) domain [79-83] (Fig. 2.2). The A domain selectively recognizes and 
binds its amino acid substrate based on specificity-conferring residues in the substrate 
binding pocket. The signature sequence motif in the binding pocket region is 
indicative of substrate preference and has been widely used for predicting substrates 
of NRPSs of unknown function, as well as guiding site-directed mutagenesis to alter 
substrate specificity of the A domain [80, 81]. After substrate binding, the A domain 
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activates the amino acid via adenylation from ATP. The aminoacyl-AMP is then 
transferred to a T domain through a covalent thioester bond to 4’-phosphopantetheine 
(Ppant arm). The T domain performs a carrier function in NRPS, covalently tethering 
the intermediate and carrying it to catalytic domains for elongation or modification. 
This mechanism facilitates the efficiency of the multi-enzyme assembly line, as 
covalent linkage between the intermediate and the T domain increases the local 
substrate concentration during reaction. In an “A-T-C” module, the C domain accepts 
an amino acylthioester intermediate from the preceding T domain and another amino 
acid building block from the following T domain, and forms a peptide bond [82]. The 
intermediate is transferred to the downstream module after the upstream module 
finishes its catalytic cycle, providing strict accuracy. 
 
 
Figure 2.2. Reaction scheme of a dimodular NRPS. The first module has a canonical 
“A-T-C” domain composition. The A domain activates its amino acid substrate via 
adenylation, and loads it onto the T domain. The T domain transfers the intermediate 
to the C domain, where a peptide bond is formed and the dipeptidyl intermediate is 
transferred to the next module. 
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In the final synthetic step, the terminal domain for product release can vary, but is 
most commonly a thioesterase (TE) domain (Fig. 2.3) [84]. TEs are derived from 
serine hydrolases, where a catalytic Ser takes the mature peptide from its cognate T 
domain, forming an acyl-O-Ser-TE intermediate. The TE domain then catalyzes 
hydrolysis to release the product with a terminal carboxyl group. In some pathways, 
intramolecular cyclization can form a cyclic lactam or lactone. The difference 
between hydrolysis and cyclization can be explained simply by different solvation 
status of the active site during catalysis [85]. If no solvent molecule is present, then 
intramolecular nucleophilic attack can produce a cyclized product. In fungi, the 
terminal TE domain is often substituted with a specialized C domain. The C domain 
catalyzes a direct nucleophilic attack of an intermolecular or intramolecular amino 
group on the thioester bond and forms a peptide bond [86]. The mature peptide is 
released and forms a linear (intermolecular attack) or cyclized (intramolecular attack) 
product. 
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Figure 2.3. Examples of NRPS termination domains. TE, C or R domains can be 
found as terminal domains of NRPS, generating different products. 
 
In some NRPS pathways, a terminal reductase (R) domain catalyzes a reductive 
release reaction. In bacteria, three types of reactions have been identified from 
different NRPS pathways with R domain termination: 2-electron reduction, 4-electron 
reduction and Dieckmann condensation [87-88] (Fig. 2.4). 2-electron reduction R 
domains produce products with a terminal aldehyde, while the 4-electron ones further 
reduce the aldehyde to an alcohol. For each step, the reaction is catalyzed by a 
canonical tyrosine-dependent short-chain dehydrogenase (SDR), with a “Ser/Thr-Tyr-
Lys” catalytic triad. The Tyr is the proton donor, and an NAD(P)H cofactor transfers 
hydride. The Lys forms a hydrogen bond to the ribose hydroxyl of the cofactor, and 
lowers the pKa of the catalytic Tyr. The Ser/Thr residue hydrogen bonds to a substrate 
hydroxyl or carbonyl group, orienting and stabilizing it to facilitate catalysis (Fig. 
2.5.C). Some R domains produce tetramic acids or derivatives via Dieckmann 
condensation. In these cases, no reduction is carried on the substrates and no cofactor 
is needed for catalysis. 
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Figure 2.4. Products of terminal reductase domains [87]. The group added by the 
terminal R domain is colored in red. 
 
Three crystal structures of bacterial NRPS terminal reductase domains have been 
reported, AusA R from Staphylococcus aureus, RNRP from Mycobacterium 
tuberculosis and MxaA R from Stigmatella aurantiaca Sga15 [87-89]. AusA, a 
dimodular NRPS in the aureusimine biosynthetic pathway [89], has an “A-T-C-A-T-
R” architecture and consumes L-Val and L-Tyr as substrates. The terminal AusA R 
domain catalyzes a 2-electron reduction reaction, producing a dipeptidyl aldehyde, 
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which is further cyclized to a dihydropyrazinone (Fig. 2.5.A). RNRP, the terminal 
domain from a Mycobacterium tuberculosis NRPS, catalyzes the release of a 
lipopeptide intermediate through a 4-electron reduction, producing an alcohol [88]. 
The reaction proceeds in two steps, the first generating an aldehyde intermediate, and 
the second reducing the aldehyde to an alcohol. The second step was reported to be 15 
times faster than the first reaction, yet no structural basis for facilitating the second 
half reaction was revealed, and no sequence motif was identified to distinguish 2-
electron from 4-electron reductases. It was proposed that the 4-electron mechanism is 
a simple repeat of 2-electron reduction, based on the fact that the AusA and RNRP 
active sites are quite similar, and share a common set of catalytic residues, which are 
derived from their SDR ancestors. MxaA is a NRPS from Stigmatella aurantiaca 
Sga15 and its terminal R domain reduces its acylthioester substrate to myxalamid S, a 
primary alcohol, via 4-electron reduction mechanism (Fig. 2.4). Compared with 
SDRs, bacterial R domains have two major structural differences: a unique N-terminal 
helix-turn-helix in the N-terminal nucleotide binding subdomain, and another helix-
turn-helix near the C-terminus, which is proposed to interact with the T domain (Fig. 
2.5.B). 
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Figure 2.5. Terminal reductase domains of bacterial NRPS [87-89]. A. The initiation 
step of aureusimine biosynthesis (figure from reference [89]). B. Crystal structure of a 
bacterial NRPS (MxaA R from Stigmatella aurantiaca Sga15, PDB ID: 4DQV, figure 
from reference [87]). The central β sheet of the Rossmann fold is colored in blue, and 
the C-term helix-turn-helix is colored in green. The cofactor, NADPH, is shown as 
stick. C. Proposed reaction mechanism of bacterial NRPS R. The nicotinamide ring 
(green) of the NADPH cofactor transfers a hydride to the substrate (red), the catalytic 
Tyr (blue) donates a proton, and the double bond is reduced. 
 
Fungal indole alkaloids are a large group of NRPS-produced products [90]. Most have 
been identified in ascomycetes, Aspergillus and Penicillium for example. In fungal 
indole alkaloid biosynthesis, most NRPSs are dimodular, producing dipeptidyl natural 
compounds. Four such pathways have been studied in collaboration with the Sherman 
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group: (-)/(+)-notoamide pathways, malbrancheamide pathway and paraherquamide 
pathway [40]. In the notoamide pathways, the NRPS (NotE/NotE’) domain 
composition is “A-T-C-A-T-C”. The first module accepts L-Pro and the second 
recognizes L-Trp, producing brevianamide F as the NRPS product [37] (Fig. 2.6.A). 
In the homologous malbrancheamide pathway, however, the proposed domain 
composition of MalG is “A-T-C-A-T-R” based on sequence analysis, suggesting a 
terminal reductive hydrolysis mechanism. Based on knowledge of bacterial NRPS R 
domains, the product was proposed to be a dipeptidyl aldehyde by the Sherman group 
[40] (Fig. 2.6.B). However, the sequence identity between this predicted fungal R 
domain and known bacterial R domains is quite low (15 - 22 %), and no structure of a 
fungal NRPS terminal reductase has been reported. Biochemical and structural 
investigation of these terminal enzymes will help to elucidate the products and the 
reaction mechanisms, and comparison with bacterial homologs may provide 
interesting discoveries and thoughts for future research. 
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Figure 2.6. The initiation step of notoamide biosynthesis (A) and the proposed 
initiation step of malbrancheamide biosynthesis (B). The (-) notoamide pathway 
NRPS (NotE) terminates with a C domain, producing brevianamide F, while the 
malbrancheamide pathway NRPS (MalG) R domain is proposed to catalyze a 
reductive release reaction. 
 
2.2 Results 
2.2.1 Proposed MalG product showed instability in vitro. 
To test the hypothesis that malbrancheamide NRPS (MalG) R catalyzes a reductive 
release reaction, L-Pro-L-Trp dipeptidyl aldehyde (17), the proposed 
malbrancheamide NRPS (MalG) product, was chemically synthesized by the 
Williams group at Colorado State University. Hong Tran in the Sherman group tested 
whether the synthetic substrate could be consumed by MalE, which was proposed to 
prenylate the NRPS product. However, the majority of 17 was spontaneously and 
irreversibly converted to 26 without any enzyme (Fig. 2.7). The structure of 26 was 
determined by LC/MS and NMR analysis, leading to the conclusion that 17 was 
unstable in vitro and rapidly oxidized to 26, as the reaction was much slower when 
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carried out in an anaerobic reaction chamber. However, 26 is unlikely to be a pathway 
intermediate in the malbrancheamide pathway, because the aromatic ring is highly 
stable and cannot easily form a diene group, which is proposed to be a key factor for 
synthesizing premalbrancheamide, the common pathway intermediate (Fig. 1.6). 
 
 
Figure 2.7. Proposed reaction scheme for spontaneous conversion of 17 to 26. The 
structure of 26 was validated by LC/MS and 1H NMR by Hong Tran. 
 
The fact that 17 was highly unstable in vitro suggests that it might not be the MalG 
product. To test this possibility, I sought to produce a MalG R domain to perform an 
in vitro assay. I analyzed the MalG sequence to identify domain boundaries for the T 
and R domains, and developed expression and purification protocols for both domains 
and the T-R didomain. Hong Tran incubated the MalG R with several dipeptidyl 
analogs. However, none of tested compounds was consumed directly by the MalG R 
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domain and no product was detected. Instead, the amino groups of the analogs were 
highly reactive and spontaneously cyclized to produce cyclo-dipeptides. 
 
2.2.2 Diffusive loading of substrates onto the MalG T domain 
In vivo, the MalG R substrate is carried on the MalG T domain with a Ppant arm, 
which may contribute to the observed inefficiency of MalG R recognizing and acting 
on unlinked dipeptidyl analogs. Thus, it seems necessary to acquire a MalG T-loaded 
substrate to identify the terminal R domain product. For that purpose, a group of 
dipeptidyl thiophenol analogs were synthesized by the Williams group (Fig. 2.S1). 
Thiophenol is an excellent leaving group and thiophenol compounds can 
spontaneously acylate protein thiols, including the Ppant thiol. In these analogs, the N 
atom of the prolyl group was replaced by a C or O atom to prevent spontaneous 
cyclization, which may compete with substrate loading. 
The MalG T domain was used for substrate loading. MalG T was co-expressed with 
sfp (a nonspecific 4'-phosphopantetheinyl transferase) [91] to transfer the Ppant arm 
onto MalG T in vivo. Intact protein mass spectrometry was used to identify the 
efficiency of Ppant transfer. Almost all (> 99%) MalG T was loaded with Ppant (Fig. 
2.8). 
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Figure 2.8. Test of the Ppant loading status of MalG T. A. HPLC elution profile of 
MalG T. B. Mass spectrum of the HPLC profile peak. C. Deconvoluted mass of MalG 
T (observed mass: 9875.71 Da, calculated mass of holo MalG T: 9875.8 Da). 
 
To load the substrate onto MalG T, holo MalG T (MalG T-Ppant) was incubated with 
the thiophenol analog under different pH (8.1, 9.5 and 10.0) and buffer (HEPPS, 
CHES and borate) conditions. LC/MS was performed to check the substrate loading 
efficiency (Fig. 2.9). The majority of MalG T (~50%) remained unloaded with 
substrate (observed mass: 9875.71 Da; calculated mass: 9875.8 Da), while ~10% was 
loaded with one substrate molecule (observed mass: 10158.57 Da; calculated mass: 
10159.8 Da). However, ~10% contained two copies of substrates (observed mass: 
10444.86 Da; calculated mass: 10443.8 Da), and ~20% had three substrates attached 
to the T domain (observed mass: 10729.43 Da; calculated mass: 10727.8 Da). The 
additional substrate loading probably occurred on one or both of the two Cys residues 
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of MalG T, as Cys is nucleophilic at high pH. Loaded species were given to MalG R, 
but no offloaded product was detected by LC/MS. In summary, the efficiency of 
substrate diffusive loading onto the MalG T domain was very low, and off-target 
loading was observed to a certain extent, which may have hampered the efficiency of 
substrate recognition and catalysis of the terminal R domain. To fix that problem, 
dipeptidyl-CoA substrates are now being synthesized chemically, and sfp-catalyzed 
enzymatic loading will be tested soon. 
 
 
Figure 2.9. Test of thiophenol substrate loading of MalG T. A. HPLC elution profile 
of substrate loaded MalG T. B. Mass spectrum of the peak of the HPLC profile. C. 
Deconvoluted mass of substrate loaded MalG T (observed mass: 9875.71 Da, 
10105.43 Da, 10158.57 Da, 10444.86 Da, 10554.57 Da, 10729.43 Da). 
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2.2.3 Structural analysis of fungal NRPS terminal reductase domain 
To help understand the function of the fungal NRPS terminal reductase domain, 
structural studies were performed on MalG R. However, the MalG R domain was 
recalcitrant to crystallization, leading to investigation of a homologous 
paraherquamide NRPS (PhqB) reductase domain. As an NRPS in the paraherquamide 
pathway, PhqB is also proposed to terminate with a reductase domain. PhqB R shares 
37% sequence identity with MalG R, and they catalyze similar reactions, based on the 
similarity of both intermediates and products of the two pathways (Fig. 2.10). 
 
 
 
Figure 2.10. Structures of paraherquamides and malbrancheamides. The common 
pathway intermediates, preparaherquamide and premalbrancheamide, are very similar 
and only differ by a methyl group, suggesting a similar pathway scheme. 
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PhqB R crystals were obtained, which diffracted to 2.6 Å to the best. Published 
bacterial R domain structures have low sequence identity to PhqB R (22% at most), so 
the initial plan to solve the structure was to produce selenomethionyl (SeMet) protein 
for phase determination by anomalous diffraction. However, the yield of soluble 
SeMet R domain was vanishingly small. A series of heavy atom soaks was carried out 
and data were collected from several crystals soaked in KI; no usable data were 
obtained from crystals soaked in other compounds. The overall poor quality of 
crystals greatly complicated the heavy atom studies. Nevertheless, five iodine sites 
were identified that appeared to be consistent in data from a few crystals, but data 
from the derivatized crystals was poorly isomorphous with the native data. 
Additionally, phase improvement from non-crystallographic symmetry (NCS) 
averaging was not available due to the single copy of PhqB R in the asymmetric unit, 
further complicating the structure determination. Attempts to solve the structure by 
molecular replacement (MR) with bacterial R domain structures finally succeeded 
using MR-ROSETTA [97], which rebuilds the initial MR probe structures with 
ROSETTA, and further rebuilds the resulting models with PHENIX.autobuild. After 
hundreds of cycles of rebuilding, more than 100 residues that were not in the initial 
MR models could be modeled in the density map. After several cycles of further 
refinement, a 2.65 Å crystal structure of paraherquamide NRPS (PhqB) reductase 
domain was obtained. 
The PhqB R is a tetramer in solution and in crystals, which differs from the MalG R 
(dimer) and the characterized bacterial NRPS R domains, which are often monomers 
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or dimers. Although tetrameric NRPS R domains are rare, their SDR ancestors are 
commonly tetramers. The PhqB R tetramer is located at a position of D2 point 
symmetry in crystals of space group I222, as each subunit interacts with all three 
other subunits, forming three different binding interfaces (Fig. 2.11). PDBePISA [92] 
was used to calculate the interface areas. The sizes of interfaces 1, 2 and 3 were 
determined to be 918 Å2, 545 Å2 and 433 Å2, covering 5.8 %, 3.5 % and 2.8 % of the 
total subunit surface area, respectively. The overall percentage of covered surface area 
is 12.1%, which is within the range of subunit interfaces of oligomeric proteins 
(>10%). The interfaces are stabilized by both hydrophobic and hydrophilic 
interactions, and the calculated ΔG of tetrameric packing is -9.3 kcal/mol. The 
tetrameric oligomer state may be inconsistent with the general observation that 
NRPSs function as monomers. However, the N-termini of the subunits are at the 
exterior of the tetramer and well separated from one another in an arrangement that 
would allow flexible tethering of a “monomeric” NRPS module. 
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Figure 2.11. Structure of the PhqB R tetramer. Each subunit contacts three other 
subunits, forming three distinct interfaces (interface 1, 2 and 3). 
 
Despite very low sequence identity (15 - 20%), the PhqB R structure resembles its 
bacterial homologs, with an N-terminal nucleotide binding subdomain and a C-
terminal substrate binding subdomain (Fig. 2.12). The N-terminal nucleotide binding 
subdomain has a typical Rossmann fold, with a parallel β sheet (β1, β2, β3, β4, β5, β6 
and β10) flanked by six α helices (α1, α2, α3, α4, α5 and α7). No cofactor is bound in 
the crystal structure, which is presumed to be NADPH. This hypothesis is further 
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supported by the observation of two conserved Arg residues (Arg65 and Arg75) in the 
structure, which may be responsible for selectively coordinating the extra phosphate 
group of NADPH over NADH (Fig. 2.13). The C-terminal subdomain, which is 
unique to NRPS terminal reductases, is composed of five α helices (α6, α8, α9, α10 
and α11) and covers the active site. The proposed active site contains three conserved 
residues (Ser177 after β5, Tyr213 and Lys217 on α5), suggestive of a canonical “Ser-
Tyr-Lys” catalytic triad and a similar reaction mechanism to bacterial NRPS terminal 
reductase domains and other Tyr-dependent SDRs (Fig. 2.13). 
 
 
Figure 2.12. Structure of the PhqB R subunit in a rainbow color scheme (N-terminus 
in blue, C-terminus in red). 
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Figure 2.13. Proposed nucleotide binding site and active site in the PhqB R structure. 
NADPH was modeled in the structure using AutoDock [136]. Two Arg residues (R65 
and R75) are proposed to coordinate the NADPH 2'-phosphate. Three conserved 
residues (S117, Y213 and K217) were found in the proposed active site. 
 
A search for structural homologs using DALI [93] revealed the three bacterial NRPS 
terminal reductase domains as closest structural homologs of PhqB R, with Z scores 
of 31.2 (MxaA R, PDB ID: 4DQV), 26.5 (RNRP, PDB ID: 4U7W) and 22.8 (AusA R, 
PDB ID: 4F6C) [87-89]. Superposition of these structures shows high levels of 
structural conservation, with several minor differences. Relative to the other 
structures, the PhqB R C-terminal α helix (α11) is tilted towards the core, and the loop 
preceding α11 is significantly shorter (Fig. 2.14). In bacterial NRPS R domains, the 
loop is extended and an extra α helix is present. This short loop feature is 
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characteristic of the PhqB R tetramer, as the loop would clash with neighboring 
subunit (magenta and cyan subunits in Fig. 2.11) if structured as in the bacterial 
homologs. Another major difference is the helix-turn-helix (α9 and α10) region of the 
C-terminal domain, which is predicted to bind the T domain. The structural difference 
may suggest different fungal and bacterial T-R interaction modes, yet more evidence 
is needed to conclude this. As to the catalytic residues, the bacterial NRPS R domains 
use “Thr-Tyr-Lys” catalytic triads to catalyze a 2-electron reduction reaction in one 
step (AusA R), or a 4-electron reduction reaction in two steps (MxaA R and RNRP). In 
the PhqB R structure, both the Tyr and Lys are conserved, while the Thr was replaced 
by a Ser, forming a canonical “Ser-Tyr-Lys” catalytic triad. The loop between the 
proposed catalytic Ser and Tyr is disordered in the PhqB R structure, suggesting the 
possibility of a conformational change upon cofactor or substrate binding. Taking all 
evidence into consideration, the fungal NRPS R domains in the malbrancheamide and 
homologous paraherquamide pathways produce either dipeptidyl aldehydes or 
dipeptidyl alcohols. However, no significant structural difference was identified to 
distinguish 2-electron reduction from 4-electron reduction, and the PhqB R structure 
offers no hint on the exact fungal NRPS reaction or products. Enzymatic 
characterization of different substrates is needed to determine the final products. 
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Figure 2.14. Superposition of PhqB R (green) and MxaA R (cyan) C-terminus. A. The 
loop that precedes the last α helix is much shorter in PhqB R (labeled in red) than in 
MxaA R (black). B. Close view of C-terminal helix-turn-helix. In MxaA R, three 
residues (S1442, F1453 and Q1455) were proposed to directly contact the MxaA T 
domain. None of these residues is conserved in PhqB R. 
 
 
 
45 
 
2.3 Discussion 
The structure of PhqB R resembles bacterial NRPS reductase domains, and suggests a 
canonical “Ser-Tyr-Lys” catalytic triad and NADPH-dependent catalytic mechanism. 
Based on that, the NRPS terminal reductase domain in the malbrancheamide pathway 
should catalyze either a two-electron or a four-electron reduction reaction, producing 
a dipeptidyl aldehyde or an alcohol. Sequence alignments and protein BLAST were 
performed to predict functions of proteins encoded by the malbrancheamide gene 
cluster by Shengying Li in the Sherman group [40] (Table 2.1).  
 
Table 2.1. Predicted functions of proteins in malbrancheamide biosynthesis 
 
Mal Proteins (AA) Proposed Function 
MalA (667) FAD-dependent halogenase 
MalB (369) Indole prenyltransferase 
MalC (264) Short-chain dehydrogenase 
MalD (336) Negative transcription regulator 
MalE (438) Indole prenyltransferase 
MalF (590) FAD-dependent oxidoreductase 
MalG (2345, A-T-C-A-T-R) Dimodular NRPS 
 
To produce premalbrancheamide, the proposed Diels-Alder product, an NRPS 
(MalG), a prenyltransferase (MalB or MalE) and maybe a short-chain dehydrogenase 
(MalC) are needed to function in defined order, as shown in Figure 2.15. To identify 
the reaction sequence of malbrancheamide biosynthesis and determine the NRPS 
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product, MalB, MalC and MalE were expressed and purified to homogeneity, activity 
tests of which will be discussed in later chapters. The aldehyde is more likely to be 
the NRPS product based on the fact that its tautomeric form 18 provides the diene 
needed for the proposed Diels-Alder reaction (Fig 2.15). No further reductive step is 
needed, and MalC was shown to be unable to oxidize dipeptidyl alcohol, the 4-
electron product, back to dipeptidyl aldehyde (Fig. 4.3). However, the aldehyde 
product was shown to be unstable in vitro (Fig. 2.7), and it is unknown how the fungi 
might overcome the problem of an unstable intermediate. 
 
 
Figure 2.15. Possible reaction sequences of the early steps in malbrancheamide 
biosynthesis. MalG, MalB, MalE and perhaps MalC may function in the sequences 
illustrated to produce premalbrancheamide. 
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Another interesting feature of the NRPS R is the T-R didomain interaction. Structural 
studies of bacterial NRPS R domains suggest that the T domain binds the C-terminal 
helix-turn-helix region of R. This hypothesis is reasonable considering the position of 
the R domain N-terminus, which connects to the T domain by a linker of fewer than 
10 amino acids. The C-terminal helix-turn-helix is near the N-terminal residue, and 
such an interaction pattern was supported by docking studies of MxaA T-R domain 
interactions [87], however, no crystal structure of the T-R didomain has been 
reported. The predicted MxaA T and R residues on the proposed binding interface are 
not conserved in MalG R or PhqB R, and structure of the C-terminal helix-turn-helix 
also differs (Fig. 2.14). Thus, it is possible that the terminal R domain interacts with T 
in a different way in the fungal and bacterial systems. Once efficient substrate loading 
onto the T domain can be achieved, the T-R didomain interaction can be tested by 
comparing substrate or cofactor consumption rates with wild-type and mutagenized R 
domains. 
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2.4 Materials and Methods 
2.4.1 Materials and strains 
NADH and NADPH were purchased commercially. E. coli XL1-Blue was used for 
vector storage, E. coli pRare, Bap1 and pGro7 were used for production of 
recombinant protein. The thiophenol compounds (Fig. 2.S1) were synthesized and 
provided by the Williams group. 
 
2.4.2 Cloning of malG T, R, T-R and phqB R 
The cDNA library of Malbranchea aurantiaca was generated by Shengying Li and 
Hong Tran. The gDNA of Penicillium fellutanum ATCC20841 was extracted by Sean 
Newmister. For cloning of malG R, PCR was used to amplify the cDNA template, 
followed by a ligation independent cloning (LIC) procedure [94, 95] to insert the 
genes into the pMCSG7 vector. For malG T, malG T-R and phqB R, the pMCSG9 
vector was used to insert the gene. PCR primers are listed in Table 2.2. The plasmids 
(pMCSG9-MalG T, pMCSG7-MalG R, pMCSG9-MalG TR and pMCSG9-PhqB R) 
were then transformed into E. coli XL1-Blue cells for plasmid storage and harvest. 
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Table 2.2. Primers used for cloning 
 
Gene Oligo Sequence (5’ -> 3’) 
malG T 
(Forward) 
TACTTCCAATCCAATGCCACACTTCAACCTCACGAAAGCAC 
malG T 
(Reverse) 
TTATCCACTTCCAATGCTAAACCCCTTCAATGAGCCTGG 
malG R 
(Forward) 
TACTTCCAATCCAATGCCATGTCTGATGATCCGCTTCTGTC 
malG R 
(Reverse) 
TTATCCACTTCCAATGCTATCACAGGACGCGTCTAAAAATACG 
malG T-R 
(Forward) 
TACTTCCAATCCAATGCCACACTTCAACCTCACGAAAGCAC 
malG T-R 
(Reverse) 
TTATCCACTTCCAATGCTATCACAGGACGCGTCTAAAAATACG 
phqB R 
(Forward) 
TACTTCCAATCCAATGCCTGGTGGGAGAGGGTGCAA 
phqB R 
(Reverse) 
TTATCCACTTCCAATGCTATTAAGAGTTGATAAGACCATTCCC 
 
2.4.3 Overexpression and purification 
For expression of malG R, E. coli pRare cells were transformed with pMCSG7-MalG 
R and grown in Terrific Broth medium (30 µg/ml ampicillin and 100 µg/ml 
spectinomycin added) at 37 °C to a O.D. 600 = ~1.0. The culture was then transferred 
to 20 °C over 1 hour, and induced with 0.4 mM IPTG. After 18-20 hours of 
incubation (20°C, 225 rpm shake), cells were harvested by centrifugation and the cell 
pellet was stored at -20 °C. MalG T and T-R were overexpressed in E. coli Bap1 cells 
with the same protocol as malG R. PhqB R was overexpressed in E. coli pGro7 cells. 
The culture was induced with 0.4 mM IPTG and 1 mg/mL L-arabinose. 
For purification, the cell pellet was resuspended in lysis buffer (10% v/v glycerol, 500 
mM NaCl, 20 mM Tris buffer pH 7.9, 20 mM imidazole, 5 mg lysozyme, 2 mg 
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DNAse and 1 mM MgCl2), and vortexed to mix for 30 min. Sonication and high 
speed centrifugation (16000 rpm, 30 min) were applied to obtain the lysate soluble 
fraction. The soluble fraction was filtered and loaded on a GE Ni-NTA HisTrap 
column (Ni-NTA buffer: 10% glycerol, 500 mM NaCl, 20 mM imidazole pH 7.9, 20 
mM Tris pH 7.9; flow rate: 3 mL/min), and was eluted with a 20 – 600 mM imidazole 
gradient (Ni-NTA buffer; flow rate: 3 mL/min; gradient time: 12 min). Fractions 
containing the R or T-R domain were pooled and incubated with TEV protease in a 
1:50 w/w ratio at 20 °C for 2 hours to remove the N-terminal His-tag or His-MBP-tag. 
The tag-free protein was dialyzed overnight at 4 °C into 10% glycerol, 2 mM DTT, 
500 mM NaCl, 20 mM Tris pH 7.9, and eluted from a Ni-NTA HisTrap column (Ni-
NTA buffer; flow rate: 3 mL/min). Further homogeneity was achieved by size-
exclusion chromatography equilibrated with 10% v/v glycerol, 300 mM NaCl, 20 mM 
Tris pH 7.9 (GE HiLoad 16/60 Superdex 200 prep grade column; flow rate: 0.5 
mL/min). SDS-PAGE was used to assess protein homogeneity, confirming >95% 
purity. Yields of purified proteins were 50 mg MalG R domain per L of E. coli 
culture, 40 mg/L MalG T-R, 5 mg/L MalG T, and 20 mg/L PhqB R. 
 
2.4.4 Crystallization and Structural Determination 
For crystallization, wild-type PhqB R protein was mixed with precipitant solution 
(10 % PEG 8000, 200 mM MgCl2, 100 mM Tris pH 7.0) in a 1:1 v/v ratio. Crystals 
grew at 4 °C within 24-48 hours, and were harvested into precipitant solution with 
25 % glycerol for cryoprotection, and flash cooled in liquid nitrogen. Diffraction data 
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were collected at the Advanced Photon Source (GM/CA beamline 23-ID-D) at an X-
ray wavelength of 1.033 Å (360° of data, 100 K, 0.2° image width). Crystals grew 
reproducibly, but had generally poor diffraction quality, most with dmin poorer than 4 
Å. The data described in Table 2.3 are the best obtained from more than 400 crystals 
screened. Data were processed with XDS [96]. The crystal structure was solved by 
MR-ROSETTA [97] using the structure of MxaA R as an initial probe. Model 
building was carried out with Coot [98]. Refinement was carried out with PHENIX 
refine [99]. 
 
2.4.5 Diffusive loading of substrates onto MalG T domain 
MalG T (50 μM) was added to 10% v/v glycerol, 50 mM NaCl, 50 mM HEPES pH 8 
or CHES pH 9.5 or borate pH 10. The loading reaction was initiated by addition of 1 
mM thiophenol substrate. The reaction mix was incubated at 20°C for 12 hours, and 
quenched with 50% v/v methanol. Centrifugation was used to remove denatured 
protein, which was resuspended in CHCl3 and analyzed by LC/MS. (Phenomenex 
Kinetix reverse-phase C18 column (40 mm × 2.1 mm, 2.6 μm), Buffer A: 0.2% v/v 
formic acid in water, Buffer B: 0.2% v/v formic acid in acetonitrile. HPLC protocol: 
5% Buffer A for 4 min, 20-100% Buffer B gradient for 4 min, 100% Buffer B for 2 
min. Flow rate: 0.5 mL/min.) 
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Appendix 
Table 2.3. Data collection and refinement statistics. 
 
 PhqB R 
Space group I 2 2 2 
Unit cell parameters (Å, °) 80.84 90.10 125.49 90 90 90 
Wavelength (Å) 1.033 
Resolution (Å) 43.43 – 2.65 (2.74 – 2.65) 
Completeness 1.00 (1.00) 
Reflections 179882 (18233) 
Unique reflections 13669 (1340) 
Multiplicity 13.2 (13.6) 
Mean I/σ 19.74 (1.03) 
Rmeas 0.074 (2.88) 
CC1/2 1 (0.66) 
CC* 1 (0.89) 
Reflections (working set) 13640 
Reflections (test set) 685 
Rwork 0.247 
Rfree 0.270 
No. of chains per AU 1 
No. of cofactors 0 
No. of non-hydrogen atoms 2467 
Avg B-value (Å2) 131.4 
Ramachandran plot: 
favored/allowed/outliers (%) 
95.4/3.8/0.8 
RMSD bonds (Å) 0.016 
RMSD angles (°) 1.70 
54 
 
Figure 2.S1. Structures of thiophenol substrate analogs (28, 29) and product standards 
(30 - 33) synthesized by the Williams group. 
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Chapter III  
MalB and MalE: Redundant prenyltransferases in malbrancheamide 
biosynthesis 
 
3.1 Introduction 
Fungal aromatic prenyltransferases are important enzymes in various kinds of fungi, 
generating a variety of prenylated secondary metabolites, such as indole alkaloids and 
polyketides. Prenylation has been shown to contribute greatly to structural diversity of 
natural products, many of which are potential candidates for anti-cancer, anti-fungal 
and anthelmintic drug design [101, 102]. Often prenylated compounds show distinct 
biological activities compared with their non-prenylated counterparts, and the prenyl 
group is essential for maintaining bioactivity [103-105]. For example, resveratrol 
suppresses the growth of Staphylococcus aureaus only when it is geranylated at the 
C4 position [103]. Since it can be difficult to synthesize these natural products 
chemically due to slow reaction rates and lack of prenylation site control, protein 
engineering and chemoenzymatic synthesis are attractive routes to produce these 
compounds for research purposes and drug design. 
Aromatic prenyltransferases can be divided into two subgroups based on which 
carbon atom of the prenyl group is involved in bond formation during catalysis: 
regular prenyltransferases form a C1-aromatic carbon bond, while reverse 
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prenyltransferases catalyze formation of a C3-aromatic carbon bond (Fig. 3.1). 
Previously whole genome sequencing, gene annotation, and enzymatic 
characterization led to identification of dozens of aromatic prenyltransferases in 
different fungal genera, including Aspergillus and Penicillium. Often the prenyl 
acceptor is the indole ring of L-tryptophan, and the primary prenyl donor is 
dimethylallyl pyrophosphate (DMAPP) [103]. 
 
 
Figure 3.1. Structures of the prenyl acceptor indole, and the appended prenyl groups, 
showing the difference between “regular” and “reverse” prenylation products (figure 
from Hong Tran). Dimethylallyl pyrophosphate (DMAPP) is the prenyl donor. 
 
One major feature of this type of modification is that the indole can be enzymatically 
prenylated at any available position (Fig. 3.2). For example, within Aspergillus 
fumigatus, FgaPT2 catalyzes C4 prenylation of L-tryptophan, while FtmPT1 
prenylates brevianamide F at the C2 position [34, 107]. NotF in Aspergillus sp. 
MF297-2, shares 30% sequence identity with FtmPT1 and acts on the same substrate 
at the same carbon atom [13]. However, FtmPT1 forms a regular carbon-carbon bond, 
while NotF catalyzes a reverse prenyltransfer reaction only. 
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Figure 3.2. Examples of indole prenyltransferases with different prenylation sites. The 
added prenyl group is colored in red. 
 
No sequence motif has been identified to distinguish any subtype of the reaction, and 
the structural basis for prenylation site control remains unclear. Also, despite broad 
substrate promiscuity, there are no known cases of fungal aromatic prenyltransferases 
that can catalyze both regular and reverse prenyltransfer reactions. To reveal the 
catalytic mechanism, as well as the structural difference between regular and reverse 
prenyltransferases, biochemical, structural and kinetic investigations have been 
performed on many characterized enzymes. For example, Fig. 3.3 shows FgaPT2, 
which catalyzes transfer of the prenyl moiety from DMAPP to the C4 position of L-
tryptophan to produce dimethylallyl tryptophan (DMAT) in the initial step of ergot 
58 
 
alkaloid biosynthesis in Aspergillus fumigatus. 
 
Figure 3.3. Structure and reaction mechanism of a typical regular prenyltransferase, 
FgaPT2. FgaPT2 catalyzes transfer of the prenyl moiety from DMAPP to the C4 
position of L-tryptophan, producing dimethylallyl tryptophan (DMAT) as the initial 
step of ergot alkaloid biosynthesis in Aspergillus fumigatus [34, 109, 110]. A. 3D 
Stereo view of an FgaPT2 subunit (figure from reference [34]). B. Proposed 
electrophilic alkylation mechanism for FgaPT2-catalyzed reaction, including 
formation of a carbocation intermediate and an arenium ion intermediate (figure from 
reference [109]). C. Cope mechanism proposed for the FgaPT2-catalyzed reaction 
(figure from reference [110]). The K174A mutant produced DMAT and a reverse-
prenylated product, suggesting a Cope rearrangement during the reaction. 
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For regular prenyltransferases, crystal structures of FgaPT2 and FtmPT1 from 
Aspergillus fumigatus have revealed a common architecture (Fig. 3.3A), represented 
by a novel β barrel topology (PT fold) [34, 36, 107, 108]. The inner barrel is formed 
by 10 anti-parallel β strands, and the outer barrel is filled with α helices, connected by 
αββα repeats [34]. For FgaPT2, two catalytic residues E89 and K174 were identified, 
as well as four tyrosine residues that are key for accommodating DMAPP. Multiple 
sequence alignments showed that most of these residues are conserved throughout this 
family of enzymes, and site-directed mutagenesis experiments have confirmed their 
necessity for maintaining enzymatic function. 
As to catalytic mechanism, thorough biochemical and structural characterization 
suggests a common dissociative (SN1) electrophilic alkylation mechanism (Fig. 3.3B) 
[34, 106]. According to this proposal, the first step of the prenyl transfer reaction is 
pyrophosphate dissociation from DMAPP, resulting in formation of a 
carbocation/pyrophosphate ion pair [109]. The carbocation intermediate then attacks 
the indole ring and forms an arenium intermediate. After deprotonation, the final 
product is generated and released from the enzyme. The observation of a positional 
isotope exchange when using 1-[18O]-DMAPP in the reaction is consistent with the 
existence of an allylic cation intermediate, and kinetic isotope effect (KIE) 
measurements also agree with the proposed mechanism. Further studies on the 
FgaPT2 K174A mutant completed the proposed mechanism, indicating the presence 
of a Cope rearrangement [110] (Fig. 3.3C). In summary, although some details are 
still unclear, prior evidence indicates that regular prenyltransferases catalyze the 
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reaction via an electrophilic alkylation mechanism. 
For reverse prenyltransferase, the crystal structure of CdpNPT from Aspergillus 
fumigatus shows a similar β barrel topology [108], and includes the same set of 
conserved residues as regular prenyltransferases, mutations of which greatly decrease 
the enzymatic activity. All evidence suggests a similar electrophilic alkylation 
mechanism, however, the existence of a carbocation intermediate has yet to be tested. 
It is hypothesized that the prenylation site control is at least partially provided by the 
active site arrangement, placing the target carbon atom closer to the prenyl donor. 
In collaboration with the Sherman group, studies have been done on 
prenyltransferases in homologous pathways in the biosynthesis of four fungal indole 
alkaloids: (-)/(+)-notoamide, paraherquamide and malbrancheamide [37, 40]. Two 
prenyltransferases, NotC and NotF, in the (-)-notoamide pathway, have been 
characterized [37]. NotF reverse prenylates brevianamide F at the C2 position, while 
NotC catalyzes a regular C7 prenyltransfer reaction on 6-OH-deoxybrevianamide E 
(Fig. 1.5). 
The malbrancheamide biosynthetic gene cluster encodes two putative 
prenyltransferases, MalB and MalE, of which MalE was shown to catalyze reverse 
prenyltransfer reaction of a dipeptidyl aldehyde analog (34) to produce the C2 
prenylated product 35 (Fig. 3.S1). Based on sequence comparison to characterized 
prenyltransferases, MalB contains a full set of catalytic residues for a classic fungal 
aromatic prenyltransfer reaction, suggesting that it may be a functional 
prenyltransferase as well. However, only one prenylation step is required to 
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synthesize malbrancheamide, the final pathway product. It is unknown whether the 
redundancy is due to gene duplication or the fact that either MalB or MalE has an 
unidentified distinct function in the pathway. It is also unclear at which step of the 
biosynthetic pathway the prenyltransfer reaction occurs. At least three possibilities 
exist (Fig. 3.4) and can be tested with proposed substrates or analogs (dipeptidyl 
aldehyde, L-Trp or T-domain linked L-Trp or dipeptide) in hand. Characterization and 
comparative analysis of MalB and MalE have helped to solve the puzzle. 
 
 
 
Figure 3.4. Possible schemes of prenyltransfer reactions catalyzed by MalB or MalE 
in malbrancheamide biosynthesis. A. The NRPS (MalG)-catalyzed reaction precedes 
the prenyltransfer reaction. B. The prenyltransfer reactions takes place when the 
substrate is loaded on the T domain of MalG. Prenylation could occur before or after 
the condensation (C) domain forms the Pro-Trp dipeptide. C. MalB or MalE 
prenylates L-Trp before the NRPS-catalyzed reaction. 
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3.2 Results 
3.2.1 Biochemical characterization of MalB as an indole prenyltransferase 
The MalB coding sequence was poorly expressed in E. coli, despite trials of various 
culture conditions, fusion partners and purification protocols. Heterologous 
expression in a baculovirus expression system finally yielded soluble MalB, which 
was purified to homogeneity. To test the enzymatic activity of MalB, a pathway 
intermediate (MalG product) candidate, L-Pro-L-Trp dipeptidyl alcohol (36), was 
used as substrate. MalB was shown to convert the dipeptidyl alcohol to a prenylated 
product, confirming its function as a prenyltransferase. 
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Figure 3.5. Enzymatic assay of MalB. A. Proposed reaction scheme of MalB 
converting 36 to 37. B. HPLC elution profile of the reaction (black: no enzyme 
control; red: reaction with MalB. S stands for substrate, and P is the product peak.). 
Detected mass spectra of the substrate and the product are shown in Fig. 3.S3. 
 
3.2.2 Substrate determination of MalB and MalE 
A hypothesis that the prenyltransfer reaction occurs on L-Trp (Fig. 3.4.C) before it is 
consumed by MalG, the non-ribosomal peptide synthetase (NRPS), was tested. 
Neither MalB nor MalE prenylated L-Trp, indicating that the prenyltransfer reaction 
is not upstream of L-Trp loading onto the NRPS T domain (Fig. 3.S5). 
The NRPS product in the pathway was proposed to be either L-Pro-L-Trp dipeptidyl 
aldehyde or dipeptidyl alcohol (36). MalE has been shown to reverse prenylate the C2 
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position of a dipeptidyl aldehyde analog 34 (Fig. 3.S1). Here, the dipeptidyl alcohol 
(36) was also tested, and MalE was shown to prenylate 36, generating a prenylated 
product (Fig. 3.6). Since MalE is capable of prenylating both the aldehyde analog and 
the alcohol, the result provides no hint on the exact malbrancheamide NRPS product. 
 
 
Figure 3.6. Prenyltransfer reaction of dipeptidyl alcohol (36) catalyzed by MalE. A. 
The proposed reaction scheme; B. HPLC elution profile of the reaction (black: no 
enzyme control; red: reaction with enzyme. S stands for substrate, and P is the product 
peak.). Detected mass spectra of the substrate and the product are shown in Fig. 3.S4. 
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3.2.3 Comparative analysis of MalB and MalE 
It was shown by Hong Tran that MalE catalyzed the C2 reverse prenyltransfer 
reaction on either the dipeptidyl aldehyde analog (34) or brevianamide F, the natural 
substrate of NotF. Incubation of 34 with MalE and DMAPP generated a product with 
a mass consistent with 35 (Fig. 3.S1). The structure was confirmed by COSY NMR 
analysis, demonstrating that MalE reverse prenylates L-Pro-L-Trp dipeptidyl analogs 
at the C2 position. 
To investigate whether MalB and MalE catalyze the same reaction, I set up separate 
reactions for both enzymes. The products were co-injected onto LC/MS. The result 
clearly showed that the MalB and MalE prenylated products co-eluted, confirming 
that MalB catalyzes the same C2 reverse prenyltransfer reaction as MalE (Fig. 3.7). 
 
 
Figure 3.7. HPLC trace of MalB and MalE reactions. The dipeptidyl alcohol (36) was 
used as a substrate, and the MalB and MalE products co-eluted. 
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3.2.4 Genetic disruption in the homologous paraherquamide pathway 
In the paraherquamide pathway (Fig. 1.4), three putative prenyltransferases PhqA, 
PhqI and PhqJ are encoded by the gene cluster, even though paraherquamide A, the 
final pathway product, has only two prenyl groups. In vivo genetic disruption of phqI 
and phqJ were performed by the Sherman group to address this question (personal 
communication from Fengan Yu). The phqJ deletion mutant profile led to an 
accumulation of preparaherquamide, a pathway intermediate, suggesting that PhqJ is 
involved in the biosynthetic pathway, and its catalyzed reaction is downstream of 
preparaherquamide production. 
PqhI on the other hand, is essential for the early steps of the pathway: Mutation of the 
coding sequence led to detection of no pathway intermediate or product. Previously 
PhqI was proposed to be the MalB homolog in the paraherquamide pathway based on 
Softberry gene annotation [136], due to the prediction that neither malB nor phqI 
contained an intron. However later sequencing results for phqI clearly showed the 
existence of a short (60-bp) intron, which is commonly found in genes that encode 
fungal indole prenyltransferases. This left malB as the only intron-free 
prenyltransferase gene among all identified fungal indole alkaloid pathways. It 
remains unclear whether this feature of malB is suggestive of an independent 
evolutionary origin or functional uniqueness. MalB has the highest sequence identity 
(34%) to PhqA in the paraherquamide pathway. Genetic disruption of phqA will be 
tested, which may provide insight into the function of the extra prenyltransferase in 
the malbrancheamide and paraherquamide pathways. 
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3.3 Discussion 
Previously it was unknown which step occurs first in the malbrancheamide pathway: 
the NRPS-catalyzed dipeptide formation, or the prenyltransfer reaction. Studies on 
the (-)-notoamide pathway showed that both prenylation steps took place after 
formation of brevianamide F, the NRPS product. NotF, the first prenyltransferase in 
the pathway, possesses strict substrate selectivity and acts only on brevianamide F, 
indicating a reaction scheme with an NRPS reaction followed by a prenyltransfer 
reaction. 
However, two major differences exist between the (-)-notoamide and the 
malbrancheamide pathways. First, only one prenyltransfer reaction is proposed to 
occur in malbrancheamide biosynthesis, compared with two confirmed prenylation 
steps in the (-)-notoamide pathway. Secondly, the domain composition of notoamide 
NRPS (NotE) and malbrancheamide NRPS (MalG) differs. The terminal domain of 
NotE is a condensation domain, producing brevianamide F as the final product; while 
MalG ends with a reductase domain, which catalyzes reduction and hydrolysis. The 
NRPS product of the malbrancheamide pathway is either a dipeptidyl aldehyde or 
dipeptidyl alcohol, with different structural features from brevianamide F. 
Thus, enzymatic tests of MalB/MalE with different putative substrates (L-Trp, 34 and 
36) are necessary to identify the correct reaction sequence of the malbrancheamide 
pathway. Our data shows that both MalB and MalE accept dipeptidyl analogs but not 
L-Trp, suggesting that the prenyltransfer reaction does not precede L-Trp loading onto 
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the NRPS T domain. It is unknown whether prenylation can occur when the dipeptide 
is attached to the NRPS, or the malbrancheamide pathway adopts the same scheme as 
the (-)-notoamide pathway. 
 
 
Figure 3.8. Two proposed mechanisms for the early steps of malbrancheamide 
biosynthesis. A. The prenyltransfer reaction occurs when the dipeptidyl intermediate is 
attached to the NRPS; B. The prenyltransfer reaction occurs after the NRPS-catalyzed 
reaction. 
 
Another question we attempted to address is the identity of the NRPS product of 
malbrancheamide pathway. Experimental data shows that both L-Pro-L-Trp alcohol 
(36) and the dipeptidyl aldehyde analog (34) can be consumed by MalE (Fig. 3.6 and 
3.S1), providing no hint on the natural product. Direct characterization of MalG and 
its terminal reductase domain is required to identify the structure of the NRPS 
product. 
Another surprising discovery is that MalB and MalE catalyze the same reaction, 
which is unprecedented in any related fungal indole alkaloid pathway. The two 
enzymes share 25% sequence identity, suggesting they may result from gene 
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duplication, yet whether one or both enzymes has an unidentified function beyond 
prenyltransfer requires further investigation. Interestingly a similar puzzle exists in 
the homologous paraherquamide pathway, where two prenyl groups are built into the 
final pathway product and three putative prenyltransferases, PhqA, PqhI and PhqJ, 
were annotated within its gene cluster. Genetic deletion of phqJ indicates its function 
being downstream of preparaherquamide formation. However, enzymatic assays of 
PhqJ in vitro showed no activity on the putative substrate preparaherquamide 
(personal communication from Sean Newmister). PhqI was shown to reverse 
prenylate the dipeptidyl alcohol at the C2 position, and its deletion led to production 
of no pathway product. Taking all available data into consideration, PhqA and PhqI 
are proposed to be MalB and MalE homologs in the paraherquamide pathway, and 
genetic disruption of phqA may provide important insights into elucidating MalB and 
MalE functions in the future. 
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3.4 Materials and Methods 
3.4.1 Materials and strains 
The dipeptide aldehyde analog (34) was synthesized by the Williams group at 
Colorado State University. L-Pro-L-Trp dipeptidyl alcohol (36) was synthesized by 
Sean Newmister in the Sherman group. L-tryptophan and DMAPP were purchased 
commercially. E. coli XL1-Blue and DH10 Bac cells were used for plasmid storage, 
E. coli BL21(DE3) pRare and Insect High-five cells (BTI-TN-5B1-4) were used for 
protein overexpression. 
 
3.4.2 Cloning of malB and malE 
The cDNA library of Malbranchea aurantiaca RRC1813 was generated by 
Shengying Li and Hong Tran in the Sherman group. For cloning of malE, PCR was 
used to amplify the cDNA template, followed by a ligation independent cloning (LIC) 
procedure [94, 95] to insert the gene into the pMCSG7 vector. PCR primers are listed 
in Table 3.1. The plasmid (pMCSG7-MalE) was then transformed into E. coli XL1-
Blue cells for plasmid storage and harvest. 
W. Clay Brown in the Smith group sub-cloned malB into a baculovirus expression 
vector that encoded an N-terminal His tag and the fusion partner maltose binding 
protein (MBP). LIC was carried out to insert malB into the vector. The plasmid was 
then transformed to DH10 Bac cells (Invitrogen). Competent cells (20 µL) were 
incubated on ice in the presence of the DNA for 30-60 minutes. SOC media (80 µL) 
was added to each tube and incubated at 37 °C for 3 hours. Each sample was plated 
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on a Q-tray well containing kanamycin, tetracycline, gentamycin, IPTG and Bluo-Gal. 
The tray was incubated for 48 hours at 37 °C. Two white colonies from each well 
were picked and patch streaked onto an indicator plate, which was incubated 
overnight at 37 °C. Colonies that remained white were considered positive. Patch 
colonies were used to inoculate overnight cultures for bacmid preps. Cultures were 
grown in 5 mL of LB with kanamycin in a 24-well block shaking at 300 RPM at 
37 °C. Cells were pelleted and then subjected to alkaline lysis. Samples were spun in 
a microfuge for 10 minutes at top speed (13000 rpm). An 800 µL aliquot was pipeted 
off and added to 800 µL of isopropanol in a fresh tube. Samples were mixed by 
inversion and then spun for 30 minutes at top speed in a microfuge. The supernatant 
was decanted and the tubes were air-dried. The pellets were resuspended in 40 µL of 
sterile water. A 7 µL aliquot of each bacmid DNA was mixed with 150 µL of media 
and 10 µL of transfection reagent in a well of a sterile 24-well block. These were 
allowed to stand for 30 minutes at room temperature in a biosafety cabinet. High-five 
cells at 2 x 106 cells/ml (850 µL) were added to each well. The block was covered 
with a sterile breather film and incubated at 27 °C with shaking at 120 RPM. After 4 
hours, an additional 3.5 mL of media with 10% FBS was added, the block was 
resealed and incubated at 27 °C with shaking at 300 RPM for 6-7 days. The block was 
spun at 1000 x g at 4 °C for 10 minutes. In a biosafety cabinet, the media was drawn 
off and placed in a cryovial and stored at 4 °C until used for infection. 
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Table 3.1. Primers used for cloing of malB and malE 
 
Gene Oligo Sequence (5’ -> 3’) 
malB 
(Forward) 
TACTTCCAATCCAATGCCATGCCTTCACAAAGCCCATATCAT 
malB 
(Reverse) 
TTATCCACTTCCAATGCTACTAGTAAGCTGACAAGTTGGTTCG 
malE 
(Forward) 
TACTTCCAATCCAATGCCATGACAGCAGGTCCGATGG 
malE 
(Reverse) 
TTATCCACTTCCAATGCTATCAAGCACCATCTCCTTGACC 
 
 
3.4.3 Overexpression and purification 
malE was overexpressed in E. coli BL21(DE3) pRare. The cells were transformed 
with pMCSG7-MalE and grown in Terrific Broth medium (30 µg/ml ampicillin and 
100 µg/ml spectinomycin added) to a O.D. 600 = ~1.0 at 37 °C. The culture was then 
transferred to 20 °C over 1 hour, and induced with 0.4mM IPTG. After 18 - 20 hours 
of incubation (20°C, 225 rpm shake), cells were harvested by centrifugation and the 
cell pellet was stored at -20°C. For purification, the cell pellet was resuspended with 
lysis buffer (10% v/v glycerol, 500 mM NaCl, 20 mM Tris buffer pH 7.9, 20 mM 
imidazole, 5 mg lysozyme, 2 mg DNAse and 1 mM MgCl2), and vortexed to mix for 
30 min. Sonication and high speed centrifugation (16000 rpm, 30 min) were applied 
to obtain the lysate soluble fraction. The soluble fraction was filtered and loaded on a 
GE Ni-NTA HisTrap column (Ni-NTA buffer: 10% glycerol, 500 mM NaCl, 20 mM 
imidazole pH 7.9, 20 mM Tris pH 7.9; flow rate: 3 mL/min), and was eluted with a 20 
– 600 mM imidazole gradient in Ni-NTA buffer (flow rate: 3 mL/min; gradient time: 
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12 min). Fractions containing MalE were pooled and incubated with TEV protease in 
a 1:50 w/w ratio at 20 °C for 2 hours to remove the N-terminal His-tag. The tag-free 
protein was dialyzed overnight at 4 °C into 10% glycerol, 2 mM DTT, 500 mM NaCl, 
20 mM Tris pH 7.9, and collected as the flow-through from a Ni-NTA HisTrap 
column (Ni-NTA buffer; flow rate: 3 mL/min). Further homogeneity was achieved by 
size-exclusion chromatography (GE HiLoad 16/60 Superdex 200 prep grade column 
equilibrated with 10% v/v glycerol, 500 mM NaCl, 20 mM Tris pH 7.9; flow rate: 0.5 
mL/min). SDS-PAGE was used to assess protein homogeneity, confirming >95% 
purity. Yield of purified protein was 50 mg MalE per L of culture. 
malB was overexpressed in High-five cells. 1L volumes of High-five cells were 
seeded at 2 x 106 cells/ml in Insect X-press media (Lonza) in 2.8 L Fernbach flasks. 
These were infected at an MOI of 2. The flasks were incubated at 20 °C with shaking 
at 140 rpm for 72 hours. The cells are harvested by centrifugation at 1000 g and 4 °C 
for 40 minutes in 1 L bottles. The media was decanted and the pellets were removed 
from the bottles with a plastic spatula and placed into Zip-loc freezer bags. The 
pellets were stored at -80 °C until purification. For purification, pellets were 
resuspended in 100 mL of lysis buffer (to 1 ml PBS add 250 µL of insect Pop-culture 
(Novagen), MgCl2 to 2 mM final, 10 µL benzonase (Novagen) and Roche EDTA free 
protease inhibitor tablet) and incubated at 25 °C with shaking for 30 min for lysis. 
The sample was centrifuged at 13000 rpm for 10 min to collect the soluble fraction. 
The soluble fraction was filtered and loaded on a GE Ni-NTA HisTrap column (Ni-
NTA buffer: 10% glycerol, 500 mM NaCl, 20 mM imidazole pH 7.9, 20 mM Tris pH 
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7.9; flow rate: 3 mL/min), and was eluted with a 20 – 600 mM imidazole gradient in 
Ni-NTA buffer (flow rate: 3 mL/min; gradient time: 12 min). Fractions containing 
MalB were pooled and incubated with TEV protease in a 1:50 w/w ratio at 20 °C for 
2 hours to remove the N-terminal His-MBP-tag. The tag-free protein was dialyzed 
overnight at 4 °C into 10% glycerol, 2 mM DTT, 500 mM NaCl, 20 mM Tris pH 7.9, 
and collected as the flow-through from a Ni-NTA HisTrap column (Ni-NTA buffer; 
flow rate: 3 mL/min). Further homogeneity was achieved by size-exclusion 
chromatography (GE HiLoad 16/60 Superdex 200 prep grade column equilibrated 
with 10% v/v glycerol, 50 mM NaCl, 20 mM Tris pH 7.9; flow rate: 0.5 mL/min). 
SDS-PAGE was used to assess protein homogeneity, confirming >95% purity. Yield 
of purified protein was 5 mg MalB per L of culture. 
 
3.4.4 Characterization of enzymatic activities 
Enzyme (50 μM) and substrate (500 μM) were added to 10% v/v glycerol, 50 mM 
NaCl, 50 mM HEPES pH 7.5, 1 mM DTT, 1 mM EDTA. The reaction was initiated 
by addition of 250 μM DMAPP. The reaction mix was incubated at 25°C for 6 hours, 
and quenched with 50% v/v methanol. Centrifugation was used to remove denatured 
protein, and the soluble fraction was collected and analyzed by LC/MS (Phenomenex 
Kinetix reverse-phase C18 column (40 mm × 2.1 mm, 2.6 μm), Buffer A: 0.2% v/v 
formic acid in water, Buffer B: 0.2% v/v formic acid in acetonitrile. HPLC protocol: 
5% Buffer A for 2 min, 5-100% Buffer B gradient for 4 min, 100% Buffer B for 2 
min. Flow rate: 0.5 mL/min.). 
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3.4.5 Protein mass spectrometry 
Protein (5 μM) was added to buffer (10% v/v glycerol, 20 mM Tris pH 7.9). LC/MS 
was used to identify the mass of the protein sample (Aeris widepore C4 column (3.6 
μm, 50 × 2.10 mm), Buffer A: 0.2% v/v formic acid in water, Buffer B: 0.2% v/v 
formic acid in acetonitrile. HPLC protocol: 5% Buffer A for 2 min, 5-100% Buffer B 
gradient for 4 min, 100% Buffer B for 2 min. Flow rate: 0.5 mL/min.). 
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Appendix 
Figure 3.S1. Enzymatic assay test of MalE. A. The reaction scheme of MalE, 
catalyzing 34 to 35. The HPLC elution profile (B), detected substrate mass (C, 
observed mass: 270.16 Da, calculated mass: 270.15 Da) and product mass (D, 
observed mass: 338.23 Da, calculated mass: 338.22 Da) are presented as below. (Data 
and figure from Hong Tran in the Sherman group) 
 
 
 
C 
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Figure 3.S2. Deconvoluted mass spectrum of MalB. Soluble MalB can only be 
obtained when expressed in insect cells. To investigate whether post-translational 
modification was present, intact protein mass spectrometry was applied. The 
experimental mass of the MalB subunit was determined to be 41839.8 Da, 342.8 Da 
higher than the calculated mass. The mass difference does not match with any 
common single type of post-translational modification, suggesting a possibility of 
multiple post-translational modifications on the protein. 
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Figure 3.S3. Detected mass spectrum of the MalB reaction, converting 36 to 37. The 
reaction scheme and HPLC profile of the reaction are shown in Fig. 3.5. A. Detected 
substrate mass: 288.17 Da (calculated mass: 288.16 Da). B. Detected product mass: 
356.24 (calculated mass: 356.23 Da). 
 
A 
 
 
B 
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Figure 3.S4. Detected mass spectrum of the MalE reaction, converting 36 to 37. The 
reaction scheme and HPLC profile of the reaction are shown in Fig. 3.6. A. Detected 
substrate mass: 288.17 Da (calculated mass: 288.16 Da). B. Detected product mass: 
356.24 (calculated mass: 356.23 Da). 
 
A 
 
 
B 
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Figure 3.S5. Enzymatic activity test of MalB/MalE with L-Trp. A. HPLC elution 
profile of the reaction. B. Detected substrate mass (observed mass: 204.95 Da, 
calculated mass: 205.09 Da). No prenylated product was detected (calculated mass: 
273.15 Da). 
 
A 
 
 
B 
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Chapter IV  
MalC: A protein of unknown function in the malbrancheamide pathway 
 
4.1   Introduction 
4.1.1   Short-chain dehydrogenases/reductases 
Short-chain dehydrogenases/reductases (SDRs) are an enzyme family that exists in 
almost all forms of life, catalyzing oxidative-reductive reactions to form various 
metabolites, hormones, etc. [111, 112]. Most SDRs are classified as oxidoreductases, 
with a few exceptions of lyses and isomerases [112]. So far over 3000 genes have 
been annotated as SDRs in databases, and in the human genome, more than 60 genes 
have been identified or proposed to be SDRs [113, 114]. The number goes up to ~150 
in certain plant species, implying their abundance and importance. In this class of 
enzymes, many have been reported to act on aliphatic alcohols, steroids, 
prostaglandins and xenobiotics [112], suggesting great potential in chemoenzymatic 
synthesis of related compounds. For sustainable chemoenzymatic synthesis, SDRs are 
also useful for cofactor regeneration, which can be costly if purchased commercially 
[116]. In fact, SDRs are now widely used for synthesis of alcohol products in industry 
[115]. SDRs are also interesting pharmacological drug targets based on  
their physiological functions. Some SDRs, such as hydroxysteroid dehydrogenases, 
affect the cellular level of their hormone products and their malfunction may lead to
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a series of metabolic syndromes [117]. Developing drugs that target related SDRs are 
of great interest. Other SDRs in microbes have been shown to participate in nutrient 
synthesis and growth regulation, studies of which may inspire the design of novel 
antibiotics [118 – 120]. 
Short-chain dehydrogenases generally have low sequence identity (15-30%) to other 
family members, yet all of them share a common structure, featured by a nucleotide 
binding subdomain typical of the Rossmann fold, a parallel β sheet flanked by α 
helices, and a C-terminal substrate binding subdomain/site [111-113] (Fig. 4.1). The 
substrate binding site is often covered by a flexible lid, which becomes ordered upon 
cofactor binding. Based on sequence lengths and cofactor preferences, SDRs can be 
further divided into two subgroups: classical SDRs and extended SDRs. Classical 
SDRs usually contain ~250 amino acids, while extended SDRs are often ~100 amino 
acids longer. For SDRs, NADH or NADPH is the most common cofactor [121].  
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Figure 4.1. Structure of a classic SDR (RasADH from Ralstonia sp. DSM 6428, PDB 
ID: 4BMS) [126-128]. Conserved motifs are colored differently (TGX3GXG motif or 
the P-loop in red, NNAG motif in yellow), and active site residues are colored in 
purple. 
 
Sequence analysis, structural investigation and site-directed mutagenesis have 
identified conserved sequence motifs and residues that are characteristic of this family 
of enzymes [122-125] (Table 4.1). An N-terminal TGX3GXG motif forms part of the 
nucleotide binding domain (the P-loop), and is responsible for coordinating the 
phosphate group of the cofactor [113]. A conserved NNAG motif follows β4, the 
central β strand of the β sheet and stabilizes the β sheet by a hydrogen bonding 
network [122]. Three conserved active site residues have been identified, forming a 
“Ser-Tyr-Lys” catalytic triad [124, 125] (Fig. 2.5.C). The Lys forms a hydrogen bond 
with a ribose hydroxyl group of the cofactor and lowers the pKa of the catalytic Tyr 
[124]. The Tyr residue is nearly invariant throughout the entire family. During the 
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reaction, it serves as a proton donor, and the C4 atom of nicotinamide transfers a 
hydride to reduce the double bond of substrates. The reaction can be catalyzed in 
either direction. The Ser is hydrogen bonded to the hydroxyl or carbonyl group of the 
substrate, orienting and stabilizing it to facilitate catalysis. Often an Asn residue near 
the active site is also conserved, which occupies a water molecule, which further 
forms a hydrogen bond with the Lys. Thus, the catalytic residues are called “Asn-Ser-
Tyr-Lys” catalytic tetrads. In the C-terminal substrate binding region of SDRs, the 
sequence identity drastically decreases as each SDR evolved to bind a particular 
substrate. Most SDRs have strict substrate selectivity and stereo specificity. 
 
Table 4.1. Sequence motifs and catalytic residues in SDRs 
 
Motif Position Function 
TGX3GXG 12-19 P-loop, cofactor phosphate binding 
NNAG 86-89 Stabilization of central β-sheet 
N-S-Y-K 111, 138 ,151, 155 Active site residues 
 
4.1.2   SDR in the malbrancheamide pathway 
In the malbrancheamide biosynthetic pathway, MalC is the only gene product 
annotated as an SDR (Table 2.1) [40]. The pathway requires only one reductive step, 
which is expected to be delivered by the terminal reductase domain of MalG, an 
NRPS, to form premalbrancheamide, the proposed Diels-Alder product. However, the 
proposed reductive NRPS product, L-Pro-L-Trp dipeptidyl aldehyde, was shown to be 
unstable in vitro (Fig. 2.7). Based on this instability, Sean Newmister proposed that 
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the NRPS reductase domain catalyzes a 4-electron reduction reaction to form a stable 
L-Pro-L-Trp dipeptidyl alcohol, which can be prenylated and subsequently oxidized 
back to an aldehyde at later steps (Fig. 4.2). MalC was proposed to catalyze the 
oxidation reaction, producing a dipeptidyl aldehyde or premalbrancheamide. In 
collaboration with the Sherman group, we have shown that the dipeptidyl alcohol can 
be prenylated by MalB or MalE, the prenyltransferases in the malbrancheamide 
pathway (Fig. 3.5 and 3.6). Biochemical and structural characterization of MalC will 
be a test of the proposal, as well as the possible function of MalC in the pathway. 
 
 
Figure 4.2. Proposed function of MalC in the early steps of malbrancheamide 
biosynthesis. Prenylated L-Pro-L-Trp dipeptidyl alcohol is the proposed native 
substrate for the MalC-catalyzed reaction. 
 
4.2   Results 
4.2.1 Test of MalC activity as short-chain dehydrogenase 
To test the hypothesis that MalC functions as short-chain dehydrogenase and oxidizes 
a prenylated dipeptide alcohol to produce an aldehyde, L-Pro-L-Trp dipeptidyl 
alcohol was incubated with a MalB, MalE and MalC enzyme mixture. Using 
dimethylallyl pyrophosphate (DMAPP) as the prenyl donor, MalB and MalE 
prenylated the dipeptidyl alcohol; however, no prenylated dipeptidyl aldehyde was 
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detected, in the presence of MalC and NAD as cofactor (Fig. 4.3). Trials of NADP as 
a cofactor candidate and buffer screens (HEPES 7.5, HEPES 8 and Tris 9) yielded the 
same result. The result indicates that MalC does not accept either the dipeptidyl 
alcohol or its prenylated product as a substrate, and MalC shows no activity of short-
chain dehydrogenase with the tested substrates. Its potential function or substrate in 
the malbrancheamide pathway requires further investigation. 
 
 
 
 
Figure 4.3. Test of potential oxidative activity of MalC. A. HPLC elution profile of 
the reaction of L-Pro-L-Trp dipeptidyl alcohol with a MalB, MalE and MalC enzyme 
mix (black: buffer control; red: reaction with enzyme mix). B. Mass spectrum of the 
substrate (observed mass: 288.17 Da; calculated mass: 288.16 Da). C. Mass spectrum 
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of detected product (observed mass: 356.24 Da; calculated mass of prenylated 
dipeptidyl alcohol: 356.23 Da). No masses were detected for the prenylated dipeptidyl 
aldehyde (336.20 Da) or premalbrancheamide (335.19 Da), the proposed Diels-Alder 
product. 
 
4.2.2 MalC structure disproves its function as a short-chain dehydrogenase 
To help understand the function of MalC, a 1.6 Å crystal structure was solved (Table 
4.3). MalC is a tetramer in solution, as shown by size-exclusion chromatography and 
multi-angle light scattering (Fig. 4.S2). Each subunit interacts with other two 
subunits, forming two distinct binding interfaces (Fig. 4.4). The tetrameric interfaces 
are stabilized primarily via hydrophobic interactions, and tetrameric association is 
commonly observed in other SDR structures. 
 
 
Figure 4.4. Structure of the MalC tetramer. Each subunit (colored differently) 
interacts with two other subunits in a dimer of dimers organization with D2 molecular 
symmetry. 
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The structure has a classical SDR fold with a Rossmann-fold nucleotide-binding 
subdomain, and a C-terminal substrate binding region (Fig. 4.5). The proposed 
substrate binding site is covered by a lid region, which is composed of α8 and an ~30 
amino acid loop preceding α8. 10 residues (206 - 215) within the loop had no electron 
density in the MalC map, indicating flexibility in the region. Weak electron density 
was also present for residues 106 - 110 in the loop region following β4, the central β 
strand of the nucleotide binding subdomain. The loop region connects β4 to α4 (part 
of the active site pocket) and separates the substrate binding site from the cofactor 
binding site. Its flexibility may be required for possible structural rearrangement upon 
cofactor or substrate binding. 
A search for structural homologs using DALI [93] revealed a group of bacterial short-
chain dehydrogenases, including RasADH [126-128]. With a “Asn-Ser-Tyr-Lys” 
catalytic tetrad, RasADH uses NADP(H) as cofactor and catalyzes oxidation of bulky-
bulky or small-bulky secondary alcohols to aldehydes. Superposition of the MalC and 
RasADH structures shows almost identical folds (RMSD = 1.2 Å), with 25% 
sequence identity (Fig. 4.5). 
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Figure 4.5. Structure of the MalC subunit. A. Rainbow color scheme presentation: N-
terminus in blue, C-terminus in red. 10 residues (206 - 215) with no electron density 
are indicated as a dashed line. B. Superposition of MalC (green) and RasADH 
structure (cyan, PDB ID: 4BMS, RMSD = 1.2 Å). Structural topology of MalC and 
RasADH is almost identical. NADPH is shown in sticks. 
 
Although structurally similar to RasADH, MalC lacks the “Asn-Ser-Tyr-Lys” 
catalytic tetrad (Fig. 4.6). No other amino acids surrounding the putative active site 
are candidates as a proton donor in substitution for the missing Tyr. This finding 
strongly discourages the proposal of MalC as a short-chain dehydrogenase/reductase. 
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Figure 4.6. Superposition of MalC proposed active site (green) and RasADH active 
site (cyan). RasADH contains the classic Asn-Ser-Tyr-Lys catalytic tetrad (black), 
while in MalC these residues are Arg-Gly-Val-Cys (red). 
 
4.2.3 MalC does not bind to NAD(P)H at μM concentration range. 
Soaking experiments of MalC crystals with NAD(P) yielded no new density in the 
proposed nucleotide binding site or elsewhere. To investigate whether MalC binds to 
NADH or NADPH, fluorescence polarization (FP) was applied (Fig. 4.7). The result 
clearly shows that MalC does not bind to the reduced form of NADH or NADPH at 
μM concentration, which is the typical Kd range for SDRs (~1 - 50 μM) [121]. Taking 
all evidence into consideration, it is conclusive that MalC does not function as a short-
chain dehydrogenase. 
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Figure 4.7. Binding assays of MalC with NADH/NADPH measured by fluorescence 
polarization. For each measurement, concentration of the cofactor was 20 μM, and the 
concentration of MalC varied from 0 to 100 μM (NADH binding in blue, NADPH 
binding in brown). 
 
4.2.4 Multiple sequence alignment of MalC suggests a biological function. 
The MalC structure clearly indicates that MalC is not a short-chain dehydrogenase. 
Moreover, MalC does not bind to NADH or NADPH at a μM concentration range. 
These data led to the hypothesis that MalC does not function as an oxidoreductase in 
the pathway, and that the malC gene was inherited from ancestors and has not yet 
been eliminated from the fungal genome through evolution. To address that 
hypothesis, a multiple sequence alignment of MalC was carried out (Fig. 4.S1). The 
result revealed that MalC has homologs in fungal indole alkaloid biosynthesis that 
share high sequence identity (40 – 50% pairwise identity), suggestive of a common 
role in the producing organisms. Sequence conservation was mapped to the MalC 
structure using ConSurf (Fig. 4.8) [129]. The proposed cofactor binding region is 
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highly conserved and contains an invariant “TGX3GXG” motif (P-loop), suggesting 
the capability of binding a nucleotide-containing molecule. The proposed substrate 
binding site is less conserved. The “Asn-Ser-Tyr-Lys” catalytic tetrad is missing in all 
MalC homologs, suggesting the possibility that the protein is redesigned to perform a 
function other than oxidation or reduction. 
 
Figure 4.8. MalC sequence conservation mapped onto the structure. Most of the 
conservation falls in the nucleotide binding subdomain, and the binding cleft. 
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4.3 Discussion 
Biochemical and structural data clearly indicate that MalC is not a short-chain 
dehydrogenase. Multiple sequence alignment shows conservation of most amino 
acids, at the positions where catalytic residues are located in SDR enzymes, 
suggestive of a conserved role for MalC and its homologs in the producing fungi. It is 
possible that MalC functions in the malbrancheamide pathway, maybe catalyzing or 
facilitating reactions other than SDR reactions. Previous studies showed that the L-
Pro-L-Trp dipeptidyl aldehyde, the proposed pathway intermediate, was highly 
unstable and spontaneously oxidized in vitro (Fig. 2.7). Perhaps a protein binds to the 
unstable dipeptidyl aldehyde and catalyzes or facilitates the proposed Diels-Alder 
reaction to produce premalbrancheamide. MalC may serve as such function. 
However, soaking of MalC crystals with premalbrancheamide, revealed no new 
density at the proposed active site pocket. 
An interesting feature of MalC and its homologs is that they co-exist with NRPS 
modules having a terminal reductase domain. In the malbrancheamide, 
paraherquamide and citrinalin biosynthetic pathways, where the terminal domain of 
an NRPS is proposed to be a reductase, a homolog of MalC is also encoded in the 
gene cluster [40]. No such SDR-annotated gene product is present in other pathways, 
(-)/(+)-notoamide pathways for example, that contain an NRPS with a terminal 
condensation domain. This suggests that MalC may function in cooperation with the 
NRPS terminal reductase domain. Previous studies have revealed groups of proteins 
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that bind and facilitate the NPRS-catalyzed reactions. A well-studied example is the 
MbtH-like protein, which serves as an integral component of bacteria NRPS [130]. 
MbtH co-purifies with its cognate NRPS in vitro, binds to the adenylation domain via 
π-stacking interactions and facilitates amino acid activation. MalC may perform a 
similar function, although there is no evidence that MalC binds to MalG, the NRPS in 
the pathway, and MalC is not related to any type of known NRPS binding 
motifs/proteins. 
Another possibility is that MalC functions as a regulatory protein, not an enzyme in 
the pathway. A well-known example is NmrA, a negative transcription regulator [131, 
132]. NmrA evolved from an SDR ancestor, yet the catalytic Tyr was missing, and the 
lid of substrate binding pocket was redesigned to bind the GATA-type transcription 
factor AreA, which regulates the expression of target genes. NmrA strongly prefers 
binding to the oxidized form of cofactors, NAD+ or NADP+, whereas the reduced 
form of the cofactors bind with a Kd in the mM range (6.0 mM in average) [133]. 
This piece of evidence is consistent with the observation that MalC does not (tightly) 
bind to NADH or NADPH. However, superposition of MalC and NmrA structures 
shows distinct differences in the transcription factor binding region, and MalC does 
not contain α11, which directly forms part of the NmrA-AreA binding interface (Fig. 
4.9). MalC also does not contain the same set of NmrA residues responsible for 
binding the AreA zinc finger, suggesting a different role. Genetic disruption of malC 
is now under way in collaboration with the Sherman group to further investigate its 
potential function in the malbrancheamide pathway. 
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Figure 4.9. Superposition of MalC (green) and NmrA-AreA zinc finger (ZF) complex 
(NmrA magenta, AreA ZF yellow, PDB ID: 2VUT, RMSD= 3.8 Å). NmrA binds to 
GATA-type transcription factor AreA ZF, and negatively regulates its gene target 
expression by competing with AreA-DNA binding. α1, α6 and α11 of NmrA interact 
with AreA ZF, occupying its DNA binding site. 
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4.4 Materials and Methods 
4.4.1 Materials and strains 
NADH and NADPH were purchased commercially. E. coli XL1-Blue was used for 
plasmid storage, E. coli BL21(DE3) was used for production of recombinant protein. 
 
4.4.2 Cloning of malC 
The cDNA library of Malbranchea aurantiaca was generated by Shengying Li and 
Hong Tran. For cloning of malC, PCR was used to amplify the cDNA template, 
followed by a ligation independent cloning (LIC) procedure [94, 95] to insert the gene 
into the pMCSG7 vector. PCR primers are listed in Table 4.2. The plasmid 
(pMCSG7-MalC) was then transformed into E. coli XL1-Blue cells for storage and 
harvest. 
 
Table 4.2. Primers used for cloning of malC 
 
Gene Oligo Sequence (5’ -> 3’) 
malC 
(Forward) TACTTCCAATCCAATGCCATGGCACCTACCAGGAGATC 
malC 
(Reverse) TTATCCACTTCCAATGCTATCAGCGCAAAAGCATCCCC 
 
4.4.3 Overexpression and purification 
For expression of wild-type malC, E. coli BL21(DE3) cells were transformed with 
pMCSG7-MalC and grown in Terrific Broth medium (30 µg/ml ampicillin added) at 
37 °C to a O.D. 600 = ~1.0. The culture was then transferred to 20 °C over 1 hour, 
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and induced with 0.4 mM IPTG. After 18 - 20 hours of incubation (20°C, 225 rpm 
shake), cells were harvested by centrifugation and the cell pellet was stored at -20 °C. 
For production of selenomethionyl (SeMet) MalC, E. coli BL21(DE3) cells were 
transformed with pMCSG7-MalC and grown in M9 minimal medium (30 µg/ml 
ampicillin added) to a O.D. 600 = ~1.0 at 37 °C. SeMet was added to a 
final concentration of 50 mg/L, and the culture was then transferred to 20 °C over 1 
hour, and induced with 0.4 mM IPTG. After 18 - 20 hours, the culture was harvested 
by centrifugation and the cell pellet was stored at -20 °C. 
For purification, the cell pellet was resuspended in lysis buffer (10% v/v glycerol, 500 
mM NaCl, 20 mM Tris buffer pH 7.9, 20 mM imidazole, 5 mg lysozyme, 2 mg 
DNAse and 1 mM MgCl2), and vortexed to mix for 30 min. Sonication and high 
speed centrifugation (16000 rpm, 30 min) were applied to obtain the lysate soluble 
fraction. The soluble fraction was filtered and loaded on a GE Ni-NTA HisTrap 
column (Ni-NTA buffer: 10% glycerol, 500 mM NaCl, 20 mM imidazole pH 7.9, 20 
mM Tris pH 7.9; flow rate: 3 mL/min), and was eluted with a 20 – 600 mM imidazole 
gradient (Ni-NTA buffer; flow rate: 3 mL/min; gradient time: 12 min). Fractions 
containing wild-type or SeMet MalC were pooled and incubated with TEV protease in 
a 1:50 w/w ratio at 20 °C for 2 hours to remove the N-terminal His-tag. The tag-free 
protein was dialyzed overnight at 4 °C into 10% glycerol, 2 mM DTT, 500 mM NaCl, 
20 mM Tris pH 7.9, and the flow-through collected from a Ni-NTA HisTrap column 
(Ni-NTA buffer; flow rate: 3 mL/min). Further homogeneity was achieved by size-
exclusion chromatography equilibrated with 10% v/v glycerol, 300 mM NaCl, 20 mM 
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Tris pH 7.9 (GE HiLoad 16/60 Superdex 200 prep grade column; flow rate: 0.5 
mL/min). SDS-PAGE was used to assess protein homogeneity, confirming >95% 
purity. Yields of purified proteins were 100 mg wild-type MalC per L of E. coli 
culture and 20 mg/L SeMet MalC. 
 
4.4.4 Crystallization and Structural Determination 
For crystallization, wild-type MalC or SeMet MalC was mixed with precipitant 
solution (32% PEG 2K MME, 0.1 M sodium acetate, 0.1 M MES pH 6.5) in a 1:1 v/v 
ratio. Crystals grew at 20 °C within 24-48 hours, and were harvested without 
additional cryoprotection and flash cooled in liquid nitrogen. Data from crystals of 
wild-type MalC were collected at the Advanced Photon Source (GM/CA beamline 
23-ID-D) at an X-ray wavelength of 1.033 Å with a Pilatus3 6M detector (360° of 
data, 100 K, 0.2° image width). Data from crystals of SeMet MalC were collected at 
an X-ray wavelength of 0.979 Å. Data were processed with XDS [96], and the SeMet 
MalC crystal structure was solved by single-wavelength anomalous diffraction (SAD) 
phasing with AutoSol [135]. Model building was carried out with Coot [98], and 
refinement was carried out with PHENIX [99]. Statistics for the crystallographic data 
and refinement are shown in Table 4.3. 
 
4.4.5 Test for enzymatic activity 
MalC (50 μM), MalE (50 μM), MalB (20 μM), DMAPP (250 μM) and NAD or 
NADP (1 mM) were added to 10% v/v glycerol, 50 mM NaCl, 50 mM HEPES pH 
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7.5. The reaction was initiated by addition of 500 μM substrate. The reaction mix was 
incubated at 25°C for 6 hours, and quenched with 50% v/v methanol. Denatured 
protein was removed by centrifugation and the soluble fraction was analyzed by 
LC/MS (Phenomenex Kinetix reverse-phase C18 column (40 mm × 2.1 mm, 2.6 μm), 
Buffer A: 0.2% v/v formic acid in water, Buffer B: 0.2% v/v formic acid in 
acetonitrile. HPLC protocol: 5% Buffer A for 2 min, 20-100% Buffer B gradient for 4 
min, 100% Buffer B for 2 min. Flow rate: 0.5 mL/min.) 
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Appendix 
Table 4.3. Data collection and refinement statistics. 
 
 MalC wild-type 
Space group P 42 
Unit cell parameters (Å, °) 79.4, 79.4, 133.6, 90, 90, 90 
Wavelength (Å) 1.033 
Resolution (Å) 26.46 - 1.59 (1.63 - 1.59) 
Completeness (%) 99 (90.3) 
Reflections 665318 (103821) 
Unique reflections 116831 (18041) 
Multiplicity 5.7 (5.8) 
Mean I/σ 13.8 (1.1) 
Rmeas 0.077 (0.78) 
CC1/2 1 (0.78) 
CC* 1 (0.89) 
Reflections (working set) 107788 (7657) 
Reflections (test set) 1884 (126) 
Rwork 0.18 (0.23) 
Rfree 0.21 (0.25) 
No. of chains per AU 4 
No. of cofactors 0 
No. of atoms protein/waters 7812/679 
Avg B-value (Å2) 32.6 
Ramachandran plot: 
favored/allowed/outliers (%) 97.7/1.8/0.4 
RMSD bonds (Å) 0.008 
RMSD angles (°) 1.063 
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Figure 4.S1. Multiple sequence alignment of MalC and its homologs. None of the 
SDR catalytic tetrad (black box) is present. The “TGX3GXG” motif (the first red box) 
in conserved, while the “NNAG” motif (the second red box) after β4 is missing in 
MalC homologs. 
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Figure 4.S2. Multi-angle light scattering analysis of purified MalC. Three statistical 
calculation methods were applied to measure the molar mass moments (Mw: weight-
average molecular weight, 105.8 ± 1.7 Da. Mn: number-average molecular weight, 
105.9 ± 1.7 Da. Mz: size-average molecular weight, 106.0 ± 6.1 Da.). The calculated 
mass of MalC subunit is 28.3 Da, and the result indicates that MalC is a tetramer in 
solution. 
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Chapter V  
Future Directions 
 
5.1 MalG: The NRPS 
The structure of the terminal reductase domain of PhqB, a MalG homolog in the 
paraherquamide pathway (Figure 1.12), resembles structures of bacterial NRPS 
terminal reductase domains, strongly indicating a similar reductive hydrolysis 
mechanism of termination. What is still unknown is whether MalG catalyzes a 2-
electron reduction to produce a peptidyl aldehyde, or a 4-electron reduction forming a 
peptidyl alcohol. Identifying the NRPS product will be a major target for future 
studies, particularly since it is the first step in the pathway. The peptidyl aldehyde was 
shown to be unstable in vitro (Fig. 2.7), suggesting the possibility of a more stable 
alcohol NRPS product. Consistent with this, the dipeptidyl alcohol has been shown to 
be stable in vitro, and able to be efficiently prenylated at the C-2 position by MalE or 
MalB, the prenyltransferases in the pathway (Fig. 3.5 and 3.6). The only missing 
piece in this scheme is a dehydrogenase to oxidize the prenylated alcohol to an 
aldehyde, which is proposed to tautomerize and produce a Diels-Alder product [40]. 
Nevertheless, a detailed enzymatic characterization of the NRPS is needed. Despite 
considerable effort, soluble full-length MalG was not obtained by heterologous 
expression in either E. coli or insect cells. A good alternative approach is to seek a 
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homolog. Currently three gene clusters (paraherquamide, citrinalin and 
chrysogenamide) homologous to the malbrancheamide gene cluster have been 
sequenced by the Sherman group, and cDNA libraries are being generated. With 
cDNAs in hand, production of recombinant MalG homologs can be tested, and 
successful enzymatic characterization with known amino acid substrates can help to 
reveal the actual NRPS product in these homologous fungal indole alkaloid pathways. 
 
5.2 Crystal engineering of PhqB R 
PhqB R crystals are very difficult to reproduce, with less than 1% of crystals having 
high-quality diffraction (better than 3.5 Å). A 2.65 Å crystal structure was solved, and 
three loops are missing in the electron density map, including the loop connecting the 
catalytic Ser and Tyr. Better diffracting crystals that can be reproduced more robustly 
are essential to future structural investigations. Crystal engineering has been used 
widely to improve reproducibility and diffraction quality of target crystals. With the 
crystal structure of PhqB R in hand, I will examine the crystal lattice contacts to 
identify any contacts that contribute to poor crystal packing, and use mutagenesis to 
create better contacts. Crystals that grow more reproducibly and have better 
diffraction quality are essential to obtaining cofactor complex. 
Also, no structure of an NRPS terminal T-R didomain has been reported and it is 
unclear how reductase domains interact with T domains. A helix-turn-helix region in 
the C-terminal domain was proposed as a T domain binding site [87]. In the PhqB R 
crystal structure, this region is largely solvent exposed, and there appears to be 
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enough space to accommodate a T domain. The purified PhqB T domain will be used 
in co-crystallization experiments. A co-crystal structure of PhqB T-R would 
significantly improve our understanding of NRPS T-R interactions and functions. 
 
5.3 MalB and MalE: Prenyltransferases 
It is intriguing that two prenyltransferases are encoded within the malbrancheamide 
gene cluster, yet only one prenylation step is required for the pathway. The same 
situation exists in the homologous paraherquamide pathway, where the gene cluster 
encodes three hypothetical prenyltransferases, while only two prenylations are 
proposed to occur. It is possible that the existence of an extra prenyltransferase gene 
is due to gene duplication, which the fungal genomes have not yet eliminated through 
evolution. It is also possible that either MalE or MalB is multi-functional and 
catalyzes other reactions in addition to prenylation. Insights should come from genetic 
disruption experiments, which are under way in collaboration with the Sherman 
group. 
Prenyltransferases are also very good candidates for protein engineering, with broad 
substrate specificity and strict prenylation site control. The structural basis for 
substrate promiscuity is the greasy pocket, which accommodates its substrate mainly 
via hydrophobic interactions. Structure-guided site-directed mutagenesis within the 
pocket can alter the substrate specificity of prenyltransferases [35]. In addition to the 
two prenyltrasferases characterized in my thesis research (MalB and MalE, Fig. 3.5 
and 3.6), three other homologous fungal indole prenyltransferases in three different 
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pathways have exhibited tight substrate specificity (personal communication from 
Sean Newmister). It is unknown whether these fungal indole alkaloid 
prenyltransferases have unique pockets that bind substrates through specific 
interactions in addition to hydrophobic contacts. Comparative structural analysis and 
site-directed mutagenesis could provide useful information on the structural basis for 
the strict substrate specificity, and guild protein engineering and chemoenzymatic 
synthesis of related novel compounds. 
 
5.4 Function of MalC 
The high sequence conservation of MalC and its homologs (40 – 50% pairwise 
identity) suggests a common role in the producing organisms. However, the crystal 
structure of MalC clearly indicates that it is not a short-chain dehydrogenase. The 
active site does not resemble any known type of catalytic chamber, as none of the 
catalytic amino acids in the SDR family is present in MalC. Thus it is unclear whether 
MalC functions as an enzyme in the malbrancheamide pathway. Genetic disruption of 
MalC or its homologs may provide useful information. Genome mining of MalC will 
also help to identify its potential partners. With the limited information available, 
MalC homologs co-locate with an NRPS having a terminal reductase domain, 
suggesting the possibility that MalC may function together with the NRPS. However, 
MalC has no sequence or structural similarity to known NRPS binding 
peptides/proteins. Once enzymatic characterization of any NRPS homologous to 
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MalG has been achieved, MalC or its holomogs can be tested in enzymatic assays to 
see if their presence affects the function of the cognate NRPSs.  
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